Document:

EX-4.1

 Exhibit 4.1 

Execution Version 
  

 
 RELATIONSHIP
AGREEMENT 
  
  

Agendia N.V. 
 and 

Athyrium Opportunities III Acquisition 2, LP 

and 
 The Major Shareholders 

 
  

24 July 2018 
  

 
  

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
	 1.
	  	DEFINITIONS AND INTERPRETATION	  	 	2	 
			
	 2.
	  	SHAREHOLDERS’ AGREEMENT; OTHER AGREEMENTS	  	 	7	 
			
	 3.
	  	SUPERVISORY BOARD	  	 	8	 
			
	 4.
	  	DECISION-MAKING	  	 	9	 
			
	 5.
	  	INFORMATION SHARING	  	 	12	 
			
	 6.
	  	REGISTRATION RIGHTS	  	 	13	 
			
	 7.
	  	TAG ALONG	  	 	21	 
			
	 8.
	  	DRAG ALONG	  	 	24	 
			
	 9.
	  	TERMINATION	  	 	26	 
			
	 10.
	  	GENERAL PROVISIONS	  	 	27	 

 SCHEDULE 1 (Deed of Accession) 

 THIS RELATIONSHIP AGREEMENT (this “Agreement”) is made on 24 July 2018 

AMONG: 
  

	(1)	 AGENDIA N.V., a public company with limited liability (naamloze vennootschap) incorporated
under the laws of the Netherlands having its registered office at Science Park 406, 1098XH Amsterdam, the Netherlands and registered with the trade register of the Chamber of Commerce with number 34185452 (the “Company”);

  

	(2)	 ATHYRIUM OPPORTUNITIES III ACQUISITION 2 LP, a limited partnership organized under the laws of the
State of Delaware having an office at 530 Fifth Avenue, 25th Floor, New York, New York 10036 (“Athyrium”); 

  

	(3)	 NORGINE B.V., a private company with limited liability (besloten vennootschap met beperkte
aansprakelijkheid) incorporated under the laws of the Netherlands, having its registered office at Cross Towers, Antonio Vivaldistraat 150, 1083HP Amsterdam, the Netherlands, and registered with the trade register of the Chamber of Commerce with
number 30127007 (“Norgine B.V.”); 

  

	(4)	 NORGINE VENTURES B.V., a private company with limited liability (besloten vennootschap met
beperkte aansprakelijkheid) incorporated under the laws of the Netherlands, having its registered office at Cross Towers, Antonio Vivaldistraat 150, 1083HP Amsterdam, the Netherlands, and registered with the trade register of the Chamber of
Commerce with number 61140120 (“Norgine Ventures B.V.”, and together with Norgine B.V., “Norgine”); 

  

	(5)	 KORYS INVESTMENTS N.V. (PREVIOUSLY NAMED: DHAM N.V.), a limited liability company (naamloze
vennootschap) incorporated under the laws of the Belgium, having its registered office at Guido Gezellestraat 126, 1654 Huizingen, Belgium and registered with the Crossroad Bank for Enterprises under number 0871.963.979
(“Korys”, and together with Norgine, the “Major Shareholders”); and 

  

	(6)	 The persons who become holders of Preference Shares (as defined below) and accede to this Agreement pursuant
to a duly signed Deed of Accession substantially in the form attached as Schedule 1. 

 The parties to this
Agreement from time to time are hereinafter collectively referred to as the “Parties” and individually as a “Party”. 

RECITALS: 
  

	(A)	 On 10 January 2013, the Major Shareholders jointly with Gendi B.V. (“Gendi”), Gilde Europe
Food & Agribusiness Fund B.V. (“Gilde”), The Global Life Science Ventures Fonds GMBH & CO KG, The Global Life Science Ventures Fund II Limited Partnership, Matignon Développement 1
(“Matignon”), Van Herk Biotech B.V. (“Van Herk”), Vlugtinvest B.V. (“Vlugtinvest”), P.H.C.J. van Doorne (“Van Doorne”), B.H.R. Hiltermann (“Hiltermann”), C.M.G.
Huijskes van Doorne (“Huijskes”), Debioinnovation S.A., Stichting Vogelgezang, Hartwig Houdstermaatschappij B.V. (“Hartwig”), C. Goddard (“Goddard”), Pietro Scalfaro (“Scalfaro”),
Henk Brulleman (“Brulleman”), Stichting Fondsen Nederlands Kankerinstituut (“SFNK”), Kurt Schmidt (“Schmidt”), R. Bernards Holding B.V., Dr. Slat Holding B.V. and L. Van ‘t Veer Holding
B.V. entered into an amended and restated shareholders’ agreement with the Company (the “Shareholders’ Agreement”) which set out the corporate governance between the parties 

  
 1 

	 	 thereto. 

  

	(B)	 The current shareholders in the Company are the Major Shareholders, Gendi, Gilde, Matignon, Van Herk,
Vlugtinvest, Van Doorne, Hiltermann, Hartwig, Goddard, Scalfaro, Brulleman, SFNK, Schmidt, R. Bernards, B.M. Sixt, L.J. van ‘t Veer, Global Life Bioventure Holdings (A), S.à r.l., Global Life Bioventure Holdings (B), S.à r.l.,
Debiopharm Diagnostics SA, Stichting Lichfield, G&M Linnaeuspark B.V., W. Wifler, H. Lindenbergh, D. Bradley, M.R. Straley and B.S. van der Baan (collectively, the “Current Shareholders”). 

 

	(C)	 Upon the date hereof, Athyrium will be the direct or indirect legal and beneficial owner of approximately
23.72% of the Shares (as defined below) and therefore would like to (i) accede to the Shareholders’ Agreement in order to benefit from the terms therein and (ii) agree with the Major Shareholders on certain arrangements as set forth
herein. 

  

	(D)	 Upon the date hereof, the Major Shareholders will be the direct or indirect legal and beneficial owners of
approximately 51.24% of the Shares. 

  

	(E)	 Pursuant to Section 16.3 of the Shareholders’ Agreement, the Shareholders’ Agreement may only
be amended or varied by an instrument in writing signed by and on behalf of all the parties thereto from time to time. As it has proven to be time consuming and cumbersome to obtain from all Current Shareholders their required consent in writing
before the Shareholders’ Agreement can be amended, this Agreement is entered into among Athyrium, the Company, and the Major Shareholders in order to agree in writing that the rights of Athyrium will be complied with to the extent set forth
herein. 

 IT IS AGREED as follows: 
  

	1.	 DEFINITIONS AND INTERPRETATION 

 

	1.1	 The following terms shall, unless the context otherwise requires, have the following meaning:

 “Admission” means the admission to listing and trading of Shares on the New York Stock
Exchange, NASDAQ, Euronext Amsterdam, or another regulated and comparable marketplace (and “Admitted” shall have a corresponding meaning); 

“Affiliate” means (i) a subsidiary (dochtermaatschappij) as referred to in section 2:24a of the
Dutch Civil Code, or (ii) an entity of which the shareholder concerned is a subsidiary (dochtermaatschappij) as referred to in section 2:24a of the Dutch Civil Code, or (iii) a group company (groepsmaatschappij) as referred
to in section 2:24b of the Dutch Civil of the shareholder concerned or of its subsidiary (dochtermaatschappij) as referred to in section 2:24a of the Dutch Civil Code, or (iv) an investment fund (beleggingsinstelling) managed by a
manager of an investment fund (beheerder van een beleggingsinstelling), each of which as referred to in section 1:1 of the Dutch Financial Supervision Act (Wet op het financieel toezicht), which manager of an investment fund is a group
company (groepsmaatschappij) as referred to in section 2:24b of the Dutch Civil of the shareholder or of its subsidiary (dochtermaatschappij) as referred to in section 2:24a of the Dutch Civil Code; 

“Agendia Group” means the Company and any other Person Controlled by the Company; 

“Articles” means the articles of association (statuten) of the Company dated as of the date hereof, as
amended from time to time; 

  
 2 

 “Associate”, as used to indicate a relationship with any
Person, means (1) any corporation or organization (other than the Company or a majority-owned subsidiary of the Company) of which such Person is an officer or partner or is, directly or indirectly, the beneficial owner of 10% or more of any
class of equity securities, (2) any trust or other estate in which such Person has a substantial beneficial interest or as to which such Person serves as trustee or in a similar fiduciary capacity, and (3) any relative or spouse of such
Person, or any relative of such spouse, who has the same home as such Person or who is a director or officer of the Company or any of its parents or subsidiaries; 

“Athyrium” has the meaning given thereto in the recitals of this Agreement; 

“Athyrium Group” means Athyrium and any other Person Controlled by Athyrium, Controlling directly or
indirectly Athyrium or directly or indirectly under the same Control as Athyrium, but excluding the Agendia Group; 

“Athyrium Supervisory Board Member” means a member of the Supervisory Board designated by Athyrium in
accordance with Clause 3; 
 “Business Day” means any day, other than a Saturday, Sunday or public
holiday, on which banks are open for business in the Netherlands; 
 “Buyer” has the meaning given thereto
in Clause 7.1; 
 “Civil Code” means the Dutch Civil Code; 

“Company” has the meaning given thereto in the opening of this Agreement; 

“Confidential Information” means any information, including the Information, of a confidential nature
concerning the Agendia Group, but excluding any information which: 
  

	 	(i)	 was in the possession of or was known to the Athyrium Group prior to its receipt of such Information from
the Agendia Group; 

  

	 	(ii)	 was or is independently developed by the Athyrium Group without the utilisation of such Confidential
Information (other than through a breach of Clause 5); 

  

	 	(iii)	 is or becomes public knowledge without the breach by the Athyrium Group of Clause 5; or

  

	 	(iv)	 is or becomes available to the Athyrium Group from a source other than the Agendia Group in circumstances
where the Athyrium Group is not aware that disclosure has been made in breach of an obligation of confidentiality; 

“Control” means with respect to a Person (other than an individual) (a) direct or indirect ownership of
more than 50% of the voting securities of such Person, (b) the right to appoint, or cause the appointment of, more than 50% of the members of the board of directors, supervisory board, or similar governing body or such Person or (c) the
right to manage, or direct the management of, on a discretionary basis, the assets of such Person, and, for the avoidance of doubt, a general partner is deemed to Control a limited partnership and, solely for the purposes of this Agreement, a fund
advised or managed directly or indirectly by a Person shall also be deemed to be Controlled by such Person (and the terms “Controlling”, “Controls” and “Controlled” shall have meanings correlative
to the foregoing); 

  
 3 

 “Corporate Governance Code” means the Dutch Corporate
Governance Code dated 8 December 2016, as amended from time to time; 
 “Deed of Accession” means a deed of
accession to this Agreement in the form attached as Schedule 1 (Deed of Accession) hereto; 
 “Deemed
Liquidation Event” means: 
  

	 	(i)	 a merger, recapitalization or consolidation in which the Company is a constituent party or a subsidiary of
the Company is a constituent party and the Company issues Shares pursuant to such merger or consolidation, except any such merger or consolidation involving the Company or a subsidiary in which the Shares outstanding immediately prior to such merger
or consolidation continue to represent, or are converted into or exchanged for shares of share capital that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the share capital of (1) the
surviving or resulting corporation; or (2) if the surviving or resulting corporation is a wholly owned subsidiary of another company immediately following such merger, recapitalization or consolidation, the parent company of such surviving or
resulting company; or 

  

	 	(ii)	 the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of
related transactions, by the Company or any subsidiary of the Company of all or substantially all the assets of the Company and its subsidiaries taken as a whole, or the sale or disposition (whether by merger, recapitalization, consolidation or
otherwise) of one or more subsidiaries of the Company if substantially all of the assets of the Company and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or
other disposition is to a wholly owned subsidiary of the Company; 

 “Demand Notice” has
the meaning given thereto in Clause 6.1(a); 
 “Excluded Registration” means (i) a registration
relating to the sale of securities to employees of the Company or a subsidiary pursuant to a management share option, share purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction or a comparable provision under
the laws of an applicable jurisdiction outside of the United States; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of
the Registrable Securities; or (iv) a registration in which the only Ordinary Shares being registered are Ordinary Shares issuable upon conversion of debt securities that are also being registered; 

“Gendi” has the meaning given thereto in the recitals of this Agreement. 

“General Meeting” means the general meeting (algemene vergadering) of shareholders of the Company; 

“Holder” means any holder of Registrable Securities who is a party to this Agreement; 

“Independent Supervisory Board Member” means a member of the Supervisory Board who is considered by the
Company to be independent in accordance with the best practice provision 2.4.8. of the Corporate Governance Code; 

  
 4 

 “Information” has the meaning given thereto in Clause
5.1; 
 “Initiating Holders” means, collectively, Holders who properly initiate a registration request
under Clause 6 of this Agreement; 
 “IPO” means the Company’s first underwritten public
offering of any Ordinary Shares on the New York Stock Exchange, NASDAQ, Euronext Amsterdam, or another regulated and comparable marketplace; 

“Korys” has the meaning given thereto in the recitals of this Agreement; 

“Korys Supervisory Board Member” means a member of the Supervisory Board designated by Korys in accordance
with Clause 3.2; 
 “Loss” or “Losses” means all damage, losses, liabilities, costs,
charges, expenses, claims and demands assessed in accordance with Section 6:95 Civil Code; 
 “Management
Board” means the management board (Raad van Bestuur) of the Company, as constituted from time to time; 

“Norgine” has the meaning given thereto in the recitals of this Agreement; 

“Norgine B.V.” has the meaning given thereto in the recitals of this Agreement; 

“Norgine Supervisory Board Member” means a member of the Supervisory Board designated by Norgine in accordance
with Clause 3.2; 
 “Norgine Ventures B.V.” has the meaning given thereto in the recitals of this
Agreement; 
 “Ordinary Shares” means the ordinary share capital of the Company; 

“Participating Shareholder” has the meaning given thereto in Clause 7.1; 

“Parties” has the meaning given thereto in the opening of this Agreement; 

“Permitted Transfer” means any proposed transfer of Shares from a Shareholder to one or more of its
Affiliates; 
 “Person” means a natural person, partnership, corporation, limited liability company,
business trust, joint stock company, trust, unincorporated association, joint venture or other entity or organisation; 

“Preference Shares” means the preference share capital of the Company; 

“Prohibited Transfer” has the meaning given thereto in Clause 7.9; 

“Proposed Sale” has the meaning given thereto in Clause 8.2; 

“Purchase and Sale Agreement” has the meaning given thereto in Clause 7.3; 

“Registrable Securities” means (i) the Ordinary Shares issuable or issued upon conversion of the
Preference Shares; (ii) any Ordinary Shares, or any Ordinary Shares issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of 

  
 5 

 the Company, acquired by the Parties after the date hereof; and
(iii) any Ordinary Shares issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares
referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned, and excluding for purposes of
Clause 6 any shares for which registration rights have terminated pursuant to Clause 6.12 of this Agreement; 

“Right of Co-Sale” has the meaning given thereto in Clause 7.1; 

“Right of First Refusal” has the meaning given thereto in Clause 7.1; 

“Sale of the Company” means either a Share Sale or a Deemed Liquidation Event; 

“SEC” means the U.S. Securities and Exchange Commission; 

“Securities Act” means the U.S. Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder; 
 “Selling Expenses” means all underwriting discounts, selling commissions, and share transfer
taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Clause 6.6; 

“Selling Investors” has the meaning given thereto in Clause 8.1; 

“Selling Shareholder” has the meaning given thereto in Clause 7.1; 

“Shares” means the issued and outstanding share capital of Company from time to time; 

“Shareholders” means all shareholders in the Company jointly (from time to time) and
“Shareholder” means each of them individually; 
 “Shareholder Representative” has the
meaning given thereto in Clause 8.1(g); 
 “Share Sale” means a transaction or series of related
transactions in which a Person, or a group of related Persons, acquires from Shareholders an amount of Shares representing more than fifty percent (50%) of the outstanding voting power of the Company; 

“Supervisory Board” means the supervisory board (Raad van Commissarissen) of the Company, as
constituted from time to time; 
 “Transfer Notice” has the meaning given thereto in Clause 7.1; and

 “Transfer Shares” has the meaning given thereto in Clause 7.1. 

 

	1.2	 In this Agreement, unless the context dictates otherwise: 

1.2.1 reference to a gender shall include all genders; 

1.2.2 reference to “include” and “including” shall be treated as reference to “include without
limitation” or “including without limitation”; 

  
 6 

 1.2.3 “or” is used in the inclusive sense of “and/or”;

 1.2.4 reference to “books, records and documents” shall refer to books, records and documents stored in any
form, including paper, magnetic media, films, microfilms, electronic storage devices and any other data carriers; 
 1.2.5
reference to any foreign legal term for any action, remedy, method or form of proceedings, court or any other legal concept or matter shall be deemed reference to the Dutch legal concept or matter, or to the legal concept or matter which most nearly
approximates the Dutch legal concept or matter as interpreted in a Dutch context; 
 1.2.6 unless the context requires
otherwise, words in the singular shall include the plural and vice versa; 
 1.2.7 unless the context requires otherwise,
reference to a paragraph, Clause or Schedule, is a reference to a paragraph, a Clause, or a Schedule to this Agreement, and the Schedules form an integral part of this Agreement; and 

1.2.8 headings are for identification only and shall not affect the interpretation of this Agreement. 

 

	2.	 SHAREHOLDERS’ AGREEMENT; OTHER AGREEMENTS 

 

	2.1	 The Company hereby agrees that it will, insofar as it is capable under Applicable Law, procure that the
rights of Athyrium and the holders of Preference Shares under this Agreement shall be protected, and the Company agrees not to propose any resolution to the Shareholders or take any action which would, if passed or taken, be uniquely detrimental to,
or conflict with, the rights of Athyrium and the holders of Preference Shares under this Agreement without the prior or simultaneous consent of the holders of a majority of the Preference Shares issued on the date hereof (the “Initially
Issued Preference Shares”). On or about the date hereof, Athyrium will accede to the Shareholders’ Agreement, so it can benefit from all rights of Investors (as defined therein) thereunder. Each Party acknowledges that in its view on
the date hereof there is no conflict as between this Agreement, the Shareholders’ Agreement, and the Articles but that, to the extent such a conflict occurs, each will seek to ensure that this Agreement shall prevail. 

 

	2.2	 The Company will use commercially reasonable efforts to procure that the Shareholders’ Agreement will
be amended as soon as reasonably feasible after the date of this Agreement in order to, inter alia, reflect the terms of this Agreement. Furthermore, the Company will use commercially reasonable efforts to procure that Section 16.3 of
the Shareholders’ Agreement will be amended such that future amendments to the Shareholders’ Agreement shall require the approval of Shareholders holding at least two-thirds of the Shares. Each Major Shareholder agrees that it will execute
an amendment to the Shareholders’ Agreement to the extent such amendment reflects the terms of this Agreement. 

  

	2.3	 Other than as set forth in the Articles, the Shareholders’ Agreement and this Agreement, each Party to
this Agreement represents that (a) it is not a Party to any agreement or understanding regarding any obligation of the Company to register under any applicable law or regulation any of its currently outstanding securities or any securities
issuable upon exercise or conversion of its currently outstanding securities, and (b) it has not entered into any agreement, whether written or oral, affecting or relating to the issuance, acquisition (including rights of first refusal or
pre-emptive rights), redemption, disposition, transfer or voting of capital shares of the Company. 

  
 7 

	2.4	 Other than to effectuate the terms of Clause 4.2, Athyrium and each Major Shareholder agrees not to
vote (at any General Meeting or otherwise) in favour of, and the Company agrees to cause its Management Board to refrain from approving upon a designation by the General Meeting, a restriction or exclusion of the pre-emptive rights set forth in the
Articles with respect to a proposed or envisaged issue of share capital of the Company without the prior or simultaneous consent of each of Athyrium, Norgine and Korys. 

 

	3.	 SUPERVISORY BOARD 

 

	3.1	 Following the date hereof and subject to Clauses 3.2 and 3.3, Athyrium shall have the right to
designate one person for nomination as a Supervisory Board member and to designate a replacement for such Supervisory Board member. Except to the extent prohibited by Applicable Law, the Company shall procure that the person who, in the future, will
be designated by Athyrium as the Athyrium Supervisory Board Member shall be nominated for appointment by the General Meeting. Athyrium shall consult with the Company as to the identity of the Athyrium Supervisory Board Member, from time to time
proposed to be appointed to the Supervisory Board by Athyrium, for the purpose of assessing the suitability of such person to serve as a member of the Supervisory Board. Any negative advice by the Company shall be based solely upon the experience,
expertise and suitability of such person for his or her role as a Supervisory Board member. For the avoidance of doubt, it is hereby noted that the consultation right shall in no event be seen as a veto right for the Company and it is up to
Athyrium’s sole discretion whether or not it will follow the Company’s advice. Such person need not be an Independent Supervisory Board Member. If the Athyrium Supervisory Board Member is to be replaced, the Company shall as soon as
reasonably practicable convene a General Meeting for the appointment of a replacement. 

  

	3.2	 Each of Athyrium, Norgine, and Korys hereby agrees to propose for nomination to the Supervisory Board one
individual selected by each of Athyrium, Norgine, and Korys; provided, that, Athyrium’s right under this Clause 3 to designate for nomination a person as a Supervisory Board member and to propose replacements for the
Athyrium Supervisory Board Member shall lapse upon the Athyrium Group directly or indirectly holding less than 15% of the aggregate Shares, and upon such occurrence Athyrium shall not have the right to designate any person for nomination by the
Supervisory Board as a Supervisory Board member. Each of Athyrium, Norgine, and Korys agrees to vote in a manner consistent with the matters agreed to by each of Athyrium, Norgine, and Korys in this Clause 3.2 (including, for the avoidance of
doubt, voting to appoint to the Supervisory Board the individuals selected for nomination). 

  

	3.3	 Upon the shareholding in the Company of Athyrium falling below the threshold stated in Clause 3.2,
Athyrium shall procure the resignation of its Supervisory Board member within ten Business Days after such occurrence, unless the chairperson of the Supervisory Board requests Athyrium before expiry of such period in writing to maintain its
Supervisory Board member for a certain period and Athyrium consents to such extension. 

  

	3.4	 The Company acknowledges that none of the Athyrium Supervisory Board Member, the Korys Supervisory Board
Member, or the Norgine Supervisory Board Member shall have a conflict of interest with the Company within the meaning of section 2:140(5) of the Civil Code by reason only of his or her affiliation with, respectively, the Athyrium Group, Korys, or
Norgine. 

  

	3.5	 In consideration for services rendered in connection with his or her duties as a member of the Supervisory
Board and so long as such individual is not a full-time investment employee or full-time consultant of Athyrium (whether or not such individual receives some compensation from Athyrium through a consulting or other arrangement), the Athyrium
Supervisory Board Member shall receive an annual fee initially equal to €25,000 

  
 8 

	 	 (subject to modification consistent with any modification of annual fees paid to similarly situated members of
the Supervisory Board) and, following receipt of detailed invoices, the Company shall reimburse the Athyrium Supervisory Board Member for expenses reasonably and directly incurred in connection with such services, provided that any expense in excess
of €1000 shall require the prior written consent of the Company in order to be reimbursed. 

  

	3.6	 The Company hereby undertakes that it shall advance expenses incurred by an Athyrium Supervisory Board
Member in defending any action, suit or proceeding and pay such expenses reasonably and directly incurred as soon as reasonably possible after having been provided with the detailed invoices, prior to the final determination of such claim; provided
that such Athyrium Supervisory Board Member agrees in writing to promptly repay such amounts to the Company if it is ultimately determined that such Athyrium Supervisory Board Member is not entitled to be indemnified under clause 20 of the Articles.

  

	4.	 DECISION-MAKING 

 

	4.1	 So long as the Athyrium Group holds at least 17,480,313 of the Initially Issued Preference Shares issued to
Athyrium on the date hereof (as adjusted for share splits, share dividends, reclassifications and the like), the Company shall refrain from, and each of Norgine and Korys shall refrain from voting in favour of, taking any of the following actions
without the prior or simultaneous approval of Athyrium: 

  

	 	(a)	 enter into any indebtedness of the Company, except where (i) such indebtedness is made available for
purchase only to Persons who are not Shareholders, and (ii) to the extent that equity securities or equity-linked securities (i.e., options, warrants and other derivative securities) of the Company are issued in connection therewith, none of
the aggregate purchase price, aggregate value, aggregate exercise price or aggregate conversion price of the equity securities or equity-linked securities is greater than 20% of the aggregate nominal value of the indebtedness; 

 

	 	(b)	 enter into any indebtedness that results in the aggregate debt of the Company (together with its
subsidiaries) exceeding an amount equal to (i) the aggregate total revenues of the Company (together with its subsidiaries) during the twelve complete calendar months immediately preceding the date of the incurrence of such indebtedness,
multiplied by (ii) 0.5; 

  

	 	(c)	 amend the Articles in a manner that adversely affects the powers, preferences or rights of the holders of
Preference Shares in a manner that is different than the effect on the rights powers, preferences or rights of the holders of other classes of the Company’s share capital; 

 

	 	(d)	 (i) reclassify, alter or amend any existing security of the Company that is pari passu with the Preference
Shares in respect of the distribution of assets on the liquidation, dissolution or winding up of the Company, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior
to the Preference Shares in respect of any such right, preference, or privilege or (ii) reclassify, alter or amend any existing security of the Company that is junior to the Preference Shares in respect of the distribution of assets on the
liquidation, dissolution or winding up of the Company, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to or pari passu with the Preference Shares in respect
of any such right, preference or privilege; 

  
 9 

	 	(e)	 enter into any Deemed Liquidation Event, unless (i) in connection therewith the holders of Preference
Shares receive an amount in cash in consideration of their liquidation preference under the Articles equal to the applicable full liquidation preference then payable under the Articles (whether or not the Articles expressly provide for the payment
of such liquidation preference in connection therewith), or (ii) such transaction is entered into with a bona fide third party (including, for this purpose, a Person other than a supervisory board member, director, officer, shareholder
or employee of the Company or any Associate of any such Person) at arms’ length; 

  

	 	(f)	 enter into any transaction or series of transactions effected by a merger (or mergers) in which the Company
issues, as consideration, Shares that rank pari passu with or senior to the Preference Shares with respect to the distribution of assets on the liquidation, dissolution or winding up of the Company, the payment of dividends or rights of
redemption (collectively, “Senior Shares”); 

  

	 	(g)	 except for transactions expressly contemplated by this Agreement as between or among the Company, on one
hand, and any supervisory board member, director, officer, shareholder or employee of the Company or any Associate of any such Person, on the other hand, enter into or become a party to any transaction with any supervisory board member, director,
officer, shareholder or employee of the Company or any Associate of any such Person, except for (i) transactions resulting in payments to or by the Company in an aggregate amount less than €500,000 and made in the ordinary course of
business and pursuant to reasonable requirements of the Company’s business and upon fair and reasonable terms that are at arms’ length and approved by a majority of the Supervisory Board; (ii) compensation amounts payable to employees
made in the ordinary course of business and pursuant to reasonable requirements of the Company’s business and upon fair and reasonable terms that are at arms’ length and approved by a majority of the Supervisory Board or the Management
Board; and (iii) financing transactions and security issuances of the Company with or to Athyrium or a Major Shareholder that are on arms’ length terms and approved by the Supervisory Board and Management Board of the Company and otherwise
in compliance with the terms of this Agreement; or 

  

	 	(h)	 allow the issuance of any securities of a subsidiary of the Company other than to the Company.

  

	4.2	 So long as the Athyrium Group holds at least a majority (on an as-converted to Ordinary Share basis) of the
issued and outstanding Preference Shares ranking senior to or pari passu with the Initially Issued Preference Shares in respect of the distribution of assets on the liquidation, dissolution or winding up of the Company, the payment of
dividends and rights of redemption, the Company shall refrain from, and each of Norgine and Korys shall refrain from voting in favour of, issuing (i) Senior Shares, or (ii) indebtedness that is convertible into, or otherwise linked to
(other than as expressly contemplated by Clause 4.1(a)), equity securities of the Company, unless: 

  

	 	(a)	 Athyrium, and each member of the Athyrium Group that is a Shareholder, together have a pre-emptive right in
connection with such issue equal to the aggregate number of Senior Shares or the aggregate face value of indebtedness convertible into, or otherwise linked to, equity securities of the Company, as applicable, envisaged to be issued, multiplied
by: 

 (i)     in the event the Athyrium Group holds less than 51%
of the Shares at the time of the Company’s dispatch of an Offer Notice (as defined below): (A) 

  
 10 

 
0.51; multiplied by (B) the lesser of one and a fraction, the numerator of which is equal to the number of Preference Shares held by Athyrium at the time of the Company’s
dispatch of such Offer Notice, and the denominator of which is equal to 24,971,875 (as adjusted for share splits, share dividends, reclassifications and the like); and 

(ii)     in the event the Athyrium Group holds 51% or more of the Shares at the time of
the Company’s dispatch of an Offer Notice: a fraction, the numerator of which is equal to the number of Shares held by Athyrium at the time of the Company’s dispatch of such Offer Notice, and the denominator of which is equal to the total
number of Shares at the time of the Company’s dispatch of such Offer Notice; and 
  

	 	(b)	 all other Shareholders have a pre-emptive right in connection with such issue in proportion to the aggregate
number of Shares held among them, which such right shall collectively equal (i) the aggregate number of Senior Shares or the aggregate face value of indebtedness convertible into, or otherwise linked to, equity securities of the Company, as
applicable, envisaged to be issued, minus (ii) the number of Senior Shares or the aggregate face value of indebtedness convertible into, or otherwise linked to, equity securities of the Company, as applicable, to which Athyrium and any
member of the Athyrium Group that is a Shareholder have a pre-emptive right in accordance with Clause 4.2(a). 

provided, that, a Shareholder that desires to commit to purchase its pre-emptive entitlement pursuant to
clause (a) or (b) immediately above must provide the Company written notice of such commitment no later than ten Business Days following such Shareholder’s receipt of written notice from the Company referencing this Clause
4.2 of this Agreement and stating (i) its bona fide intention to offer Senior Shares or indebtedness that is convertible into, or otherwise linked to, equity securities of the Company, (ii) the number of such Senior Shares or
relevant indebtedness to be issued, and (iii) the terms of the financing, including, if applicable, the envisaged rights, preferences, and privileges of the Senior Shares and the envisaged share price (an “Offer Notice”), and a
Shareholder’s failure to provide such notice by such date shall be deemed an irrevocable forfeiture of its pre-emptive rights in connection with such issue; 

provided, further, that, if a Shareholder who is entitled to a pre-emptive right pursuant to clause
(b) immediately above does not or does not fully exercise such right, (i) the other Shareholders (excluding each member of the Athyrium Group) shall be entitled to pre-emptive rights with respect to the Senior Shares or indebtedness
convertible into, or otherwise linked to, equity securities of the Company that has not been claimed, in proportion to the aggregate number of Shares held among such other Shareholders, and (ii) if such other Shareholders collectively do not or
do not fully exercise such pre-emptive rights in connection with such unclaimed Senior Shares or indebtedness convertible into equity securities of the Company, then Athyrium shall have a pre-emptive right on any such remaining Senior Shares or
indebtedness convertible into, or otherwise linked to, equity securities of the Company. 
 If the securities referred to in
an Offer Notice are not elected to be purchased or acquired by Shareholders as described in this Clause 4.2, the Company may, during the 75-day period following the expiration of the periods described in this Clause 4.2 above, offer
and sell the remaining portion of such securities to any Person or Persons at a price not less than, and upon terms no more favourable to the offeree than, those specified in the applicable Offer Notice. If the Company does not enter into an
agreement for the sale of such securities within the 75-day period described above, then the right provided under this 

  
 11 

 
Clause 4.2 shall be revived and no such securities shall be offered or sold unless first reoffered to the Shareholders pursuant to the terms of this Clause 4.2. 

To the extent any provision in this Clause 4.2 is given for the benefit of a Shareholder that is not a Party, such
provision constitutes an irrevocable third-party stipulation for no consideration (onherroepelijk derdenbeding om niet) for the benefit of such Shareholder. 
  

	4.3	 So long as any Party holds any Preference Shares, each Party agrees not to vote (in person, by proxy or by
action by written consent, as applicable) in favour of any public listing other than an IPO, and only in favour of an IPO in the event: 

  

	 	(a)	 (i) in satisfaction of the liquidation preference then payable under the Articles in connection with such
IPO, the holders of Preference Shares receive an amount equal to or higher than such liquidation preference, whether in the form of cash or by delivery of additional Admitted Shares in lieu of cash (and such Admitted Shares are valued at the initial
offer price in connection with the IPO and may be subject to a market-standard “lock-up” period) or a mix thereof, such form to be determined by the Company in its sole discretion, (ii) the IPO results in an offer price per share of
at least €1.20 (as adjusted for share splits, share dividends, reclassifications and the like), and in aggregate cash proceeds to the Company of not less than $40,000,000, and (iii) the IPO results in all issued and outstanding Preference
Shares being converted into Ordinary Shares in accordance with the Articles; or 

  

	 	(b)	 holders of a majority of the Initially Issued Preference Shares that are issued and outstanding at the time
of the vote on the IPO deliver their prior or simultaneous approval of or consent to such IPO. 

  

	5.	 INFORMATION SHARING 

 

	5.1	 So long as the Athyrium Group holds at least 6,242,969 of the Initially Issued Preference Shares issued to
Athyrium on the date hereof (as adjusted for share splits, share dividends, reclassifications and the like), the Company shall provide or procure that Athyrium is provided with the following information (collectively, the
“Information”): 

  

	 	(a)	 not later than one month before the start of each financial year of the Company, an annual budget, split
monthly and/or quarterly, for the Company for that financial year, including cash flow forecasts and detailed notes; 

  

	 	(b)	 as soon as practicable (and in any event within six months after the end of each financial year), the
audited (consolidated) accounts of the Company (and its subsidiaries) for that year; 

  

	 	(c)	 as soon as practicable (and in any event within fifteen (15) Business Days after the end of each month
or quarter), the monthly and quarterly unaudited management accounts which shall consist of a balance sheet, profit and loss account, a comparison with budget, cash flow statement, cash flow forecast for the following six months and management
commentary for the Company, all on the basis of accounting principles and policies approved by the Supervisory Board, consistently applied, as well as a brief description of all major pending management issues concerning the Company. The monthly
management report will include commercial and operational information the substance and form to be agreed upon by the Management Board and the Supervisory Board; and 

  
 12 

	 	(d)	 such other financial or management information as Athyrium may from time to time reasonably request.

  

	5.2	 The Company shall use its best endeavours to ensure that Athyrium shall at all times be able to meet such
management and personnel of the Company as may reasonably be designed by it, upon reasonable notice to the Company, for the purpose of consulting with management, obtaining information regarding the business and prospects of the Company.

  

	5.3	 Athyrium shall procure that all Information provided to it or to any member of the Athyrium Group pursuant
to Clause 5.1 shall be treated as Confidential Information (subject to the exceptions applicable thereto) and shall be used in accordance with all applicable laws and regulations. 

 

	5.4	 Athyrium shall ensure that Confidential Information received by any member of the Athyrium Group will be
maintained as confidential and only be disclosed: 

  

	 	(a)	 to the extent necessary to any member of the Athyrium Group and any member of the Athyrium Group’s
respective directors, officers, employees and professional advisors, on terms that such recipient shall only use such Confidential Information in connection with that Person’s legitimate interests as a shareholder or creditor, or representative
or advisor of a shareholder or creditor of the Company, and provided that Athyrium shall procure that such persons are made aware of the terms of this Clause 5.4 and shall use its best endeavours to procure that such persons adhere to these
terms as if they were bound by the provision of this Clause 5.4 and on the basis that Athyrium shall be responsible for any breach of confidentiality by such recipient; 

 

	 	(b)	 if requested or required by applicable law or by a competent court; 

 

	 	(c)	 if requested or required by any competent securities exchange or competent regulatory or governmental body;

  

	 	(d)	 if necessary to enforce this Agreement in court proceedings; 

 

	 	(e)	 if necessary to put up a defence in any court proceedings; or 

 

	 	(f)	 if the Company has given its written consent to disclosure. 

In the event of a disclosure of Confidential Information pursuant to subsections (b) – (f) immediately above, Athyrium
shall consult with the Company as to the contents, form and timing of the disclosure to be made, to the extent legally permissible and reasonably practicable. 
  

	6.	 REGISTRATION RIGHTS 

The Company covenants and agrees as follows: 
  

	6.1	 Demand Registrations. 

 

	 	(a)	 If at any time after the earlier of (i) four years after the date of this Agreement or (ii) 180 days
after the effective date of the registration statement for the IPO, the Company receives a request from Holders of at least two-thirds of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement in the
United States, or a comparable filing instrument if the IPO was not in the United States and the Shares are not then Admitted in the United States, with 

  
 13 

	 	 
respect to at least one-third of the Registrable Securities then outstanding (or a lesser percentage if the anticipated aggregate offering price, net of Selling Expenses, would exceed USD $40
million), then the Company shall (x) within 15 days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in
any event within 90 days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act, or a comparable filing instrument if the IPO was not in the United States and the Shares are
not then Admitted in the United States, covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as
specified by notice given by each such Holder to the Company within 30 days of the date the Demand Notice is given, and in each case, subject to the limitations of Clause 6.1(c) and Clause 6.3. 

 

	 	(b)	 If at any time when it is eligible to use a Form S-3 registration statement or a comparable filing
instrument in an applicable jurisdiction outside of the United States, the Company receives a request from Holders of at least 20% of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement or a comparable
filing instrument in a jurisdiction outside of the United States, with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least USD $10 million, then the
Company shall (i) within 10 days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within 45 days after the date such request is
given by the Initiating Holders, file the requested registration statement covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within
20 days of the date the Demand Notice is given, and in each case, subject to the limitations of Clause 6.1(c) and Clause 6.3. 

  

	 	(c)	 Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration
pursuant to this Clause 6.1 a certificate signed by the Company’s chief executive officer stating that in the good-faith judgment of the Supervisory Board it would be materially detrimental to the Company and the Shareholders for such
registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition,
corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the
Company unable to comply with requirements under applicable securities laws, then the Company shall have the right to defer taking action with respect to such filing for a period of not more than 90 days after the request of the Initiating Holders
is given; provided, however, that the Company may not invoke this right more than once in any 12-month period; and provided further that the Company shall not register any securities for its own account or that of any other shareholder during such
90-day period other than an Excluded Registration. 

  

	 	(d)	 The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to
Clause 6.1(a) (i) during the period that is 60 days before the Company’s good faith estimate of the date of filing of, and ending on a date that is 180 days after the effective date of, a Company-initiated registration; provided
that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) 

  
 14 

	 	 
after the Company has effected one registration pursuant to Clause 6.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be
immediately registered on Form S-3, or a comparable filing instrument in a jurisdiction outside of the United States, pursuant to a request made pursuant to Clause 6.1(b). The Company shall not be obligated to effect, or to take any action to
effect, any registration pursuant to Clause 6.1(b) (i) during the period that is 30 days before the Company’s good faith estimate of the date of filing of, and ending on a date that is 90 days after the effective date of, a
Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected one registration
pursuant to Clause 6.1(b) within the 12 month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Clause 6.1(d) until such time as the
applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand
registration statement pursuant to Clause 6.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Clause 6.1(d). 

 

	6.2	 Company Registration. If the Company proposes to register (including, for this purpose, a
registration effected by the Company for Shareholders other than the Holders) any of its Shares in connection with the public offering of such Shares solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly
give each Holder notice of such registration. Upon the request of each Holder given within 20 days after such notice is given by the Company, the Company shall, subject to the provisions of Clause 6.3, cause to be registered all of the
Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Clause 6.2 before the effective date of such
registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Clause 6.6.

  

	6.3	 Underwriting Requirements. 

 

	 	(a)	 If, pursuant to Clause 6.1, the Initiating Holders intend to distribute the Registrable Securities
covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Clause 6.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be
selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders (on an as-converted to Ordinary Share basis). In such event, the right of any Holder to include such Holder’s Registrable Securities
in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to
distribute their securities through such underwriting shall (together with the Company as provided in Clause 6.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting.
Notwithstanding any other provision of this Clause 6.3, if the underwriter(s) advise the Initiating Holders in writing that marketing factors require a limitation on the number of Shares to be underwritten, then the Initiating Holders shall
so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities,
including the Initiating Holders, in proportion (as nearly as practicable) to the 

  
 15 

	 	 
number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable
Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. 

 

	 	(b)	 In connection with any offering involving an underwriting of Shares pursuant to Clause 6.2, the
Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such
quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by Shareholders to be included in such
offering exceeds the number of Shares to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering
only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the
Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the
number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities
included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced
below 25% of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other
Shareholder’s securities are included in such offering. 

  

	6.4	 Obligations of the Company. Whenever required under this Clause 6 to effect the registration
of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

  

	 	(a)	 prepare and file a registration statement with respect to such Registrable Securities and use its
commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period
of up to 120 days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that such 120-day period shall be extended for a period of time equal to the period the Holder refrains, at
the request of an underwriter of Ordinary Shares (or other securities) of the Company, from selling any securities included in such registration; 

  

	 	(b)	 prepare and file such amendments and supplements to such registration statement, and the prospectus used in
connection with such registration statement, as may be necessary to comply with the Securities Act (or such other applicable law of a jurisdiction outside of the United States) in order to enable the disposition of all securities covered by such
registration statement; 

  
 16 

	 	(c)	 furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus,
as required by the Securities Act (or such other applicable law of a jurisdiction outside of the United States), and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities;

  

	 	(d)	 use its commercially reasonable efforts to register and qualify the securities covered by such registration
statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general consent to service
of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act (or such other applicable law of a jurisdiction outside of the United States);

  

	 	(e)	 in the event of any underwritten public offering, enter into and perform its obligations under an
underwriting agreement, in usual and customary form, with the underwriter(s) of such offering; 

  

	 	(f)	 use its commercially reasonable efforts to cause all such Registrable Securities covered by such
registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

 

	 	(g)	 provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement
and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

  

	 	(h)	 promptly make available for inspection by the selling Holders, any underwriter(s) participating in any
disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of
the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or
advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

  

	 	(i)	 notify each selling Holder, promptly after the Company receives notice thereof, of the time when such
registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

  

	 	(j)	 after such registration statement becomes effective, notify each selling Holder of any request by the SEC
that the Company amend or supplement such registration statement or prospectus. 

 In addition, the Company
shall ensure that, at all times after any registration statement covering a public offering of securities of the Company shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading
program under Rule 10b5-1 of the Exchange Act or a comparable law, rule or regulation of a jurisdiction outside the United States. 

  
 17 

	6.5	 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any
action pursuant to this Clause 6 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method
of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

  

	6.6	 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with
registrations, filings, or qualifications pursuant to this Clause 6, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees
and disbursements, not to exceed US $50,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company. All Selling Expenses relating to Registrable Securities registered pursuant to
this Clause 6 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

  

	6.7	 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or
otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Clause 6. 

 

	6.8	 Indemnification. If any Registrable Securities are included in a registration statement under this
Clause 6: 

  

	 	(a)	 To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the
partners, members, officers, directors, and shareholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such
Holder or underwriter within the meaning of the Securities Act or the Exchange Act, or any comparable law under a jurisdiction outside of the United States, against any damages, and the Company will pay to each such Holder, underwriter, controlling
Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which damages may result, as such expenses are incurred; provided, however,
that the indemnity agreement contained in this Clause 6.8 shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably
withheld, nor shall the Company be liable for any damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder,
underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. 

  

	 	(b)	 To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold
harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company, legal counsel and accountants for the Company, any underwriter, any other Holder selling
securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any damages, in each case only to the extent that such damages arise out of or are based upon actions or omissions made in
reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned
Person any legal or other expenses 

  
 18 

	 	 
reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which damages may result, as such expenses are incurred; provided, however, that the
indemnity agreement contained in this Clause 6.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably
withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Clause 6.8(b) and Clause 6.8(d) exceed the proceeds from the offering received by such Holder
(net of any Selling Expenses paid by such Holder), except in the case of fraud or wilful misconduct by such Holder. 

  

	 	(c)	 Promptly after receipt by an indemnified party under this Clause 6.8(b) of notice of the commencement
of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Clause 6.8,
give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to
which notice has been given, and to assume the defence thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by
one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate
due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. 

  

	 	(d)	 To provide for just and equitable contribution to joint liability in any case in which either: (i) any
party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Clause 6.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Clause 6.8 provides for indemnification in such case, or
(ii) contribution may be required on the part of any party hereto for which indemnification is provided under this Clause 6.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages,
liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements,
omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be
determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the
indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case (x) no Holder will be required to contribute
any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of “fraudulent misrepresentation” (applying the
meaning of Clause 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability

  
 19 

	 	 
pursuant to this Clause 6.8(d), when combined with the amounts paid or payable by such Holder pursuant to Clause 6.8(b), exceed the proceeds from the offering received by such
Holder (net of any Selling Expenses paid by such Holder), except in the case of wilful misconduct or fraud by such Holder. 

  

	 	(e)	 Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten
public offering, the obligations of the Company and Holders under this Clause 6.8 shall survive the completion of any offering of Registrable Securities in a registration under this Clause 6, and otherwise shall survive the termination
of this Agreement. 

  

	6.9	 Reports. If the shares of the Company are Admitted in the United States, with a view to making
available to the Holders the benefits of SEC Rule 144 and any other rule or regulation that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3 (or comparable
instrument under the laws of a jurisdiction outside of the United States), the Company shall: 

  

	 	(a)	 make and keep available adequate current public information (as those terms are understood and defined in
SEC Rule 144) at all times after the effective date of the registration statement filed by the Company for the IPO; 

  

	 	(b)	 use commercially reasonable efforts to file in a timely manner all reports and other documents required of
the Company (at any time after the Company has become subject to such reporting requirements); and 

  

	 	(c)	 furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request
(i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements applicable to the class of securities comprising the Registrable Securities, or that it qualifies as a registrant whose
securities may be resold; (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing
any Holder of any rule or regulation that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements) or pursuant to Form S-3 (at any time after the Company so
qualifies to use such form). 

  

	6.10	 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company
shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that (i) would provide to
such holder the right to include securities in any registration on other than either a pro rata basis with respect to the Registrable Securities or on a subordinate basis after all Holders have had the opportunity to include in the registration and
offering all shares of Registrable Securities that they wish to so include; or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder; provided that this
limitation shall not apply to any Shareholder who becomes a party to this Agreement. 

  

	6.11	 “Market Stand off” Agreement. Each Holder hereby agrees that it will not, without the prior
written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company of shares of its equity securities and ending on the date specified by the Company and the
managing underwriter (such period not to exceed one hundred eighty (180) days in the case of the 

  
 20 

	 	 
IPO, or such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports, and
(2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto, or any comparable rules or regulations
applicable in a jurisdiction outside the United States) or ninety (90) days in the case of any registration other than the IPO, or such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on
(1) the publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor
provisions or amendments thereto, or any comparable rules or regulations applicable in a jurisdiction outside the United States) (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or
contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any Ordinary Shares or any securities convertible into or exercisable or exchangeable (directly or indirectly) for
Ordinary Shares held immediately before the effective date of the registration statement for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of
ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Ordinary Shares or other securities, in cash, or otherwise. The foregoing provisions of this Clause 6.11
shall apply only to the IPO, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall be applicable to the Holders only if all officers and directors are subject to the same restrictions and the
Company uses commercially reasonable efforts to obtain a similar agreement from all shareholders individually owning more than 5% of the Company’s outstanding Ordinary Shares (after giving effect to conversion into Ordinary Shares of all
outstanding preference shares. To the extent any provision in this Clause 6.11 is given for the benefit of an underwriter in connection with such registration, such provision constitutes an irrevocable third-party stipulation for no
consideration (onherroepelijk derdenbeding om niet) for the benefit of such underwriter. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are
consistent with this Clause 6.11 or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all
Holders subject to such agreements, based on the number of shares subject to such agreements. 

  

	6.12	 Termination of Registration Rights. The right of any Holder to request registration or inclusion of
Registrable Securities in any registration pursuant to Clause 6.1 or Clause 6.2 shall terminate upon the earlier of (i) the fourth anniversary of the IPO and (b) the consummation of a Sale of the Company.

  

	7.	 TAG ALONG 

  

	7.1	 Other than as set forth in Clause 7.11, if any Shares proposed to be transferred (the
“Transfer Shares”) by Athyrium or a Major Shareholder (the “Selling Shareholder”) are not purchased in full by Shareholders pursuant to the right of first refusal set forth in Article 11 of the Articles (the
“Right of First Refusal”) or are otherwise eligible to be sold by the Selling Shareholder to a proposed transferee (the “Buyer”), such Selling Shareholder hereby agrees that each Shareholder may elect to exercise
its right to participate in such proposed transfer (the “Right of Co-Sale”) on a pro rata basis (and on an as-converted to Ordinary Share basis) and on the same terms and conditions specified in a transfer notice to be prepared by
the Selling Shareholder in connection with such proposed transfer (the “Transfer Notice”). Each Shareholder who desires to exercise its Right of Co-Sale (each, a “Participating Shareholder”) must give the Company
and the 

  
 21 

	 	 
Selling Shareholder written notice to that effect within 15 days of receipt of the Transfer Notice. 

  

	7.2	 Each Participating Shareholder may include in the proposed transfer all or any part of such Participating
Shareholder’s Shares equal to the product obtained by multiplying (i) the aggregate number of Transfer Shares subject to the proposed transfer (excluding shares purchased by the Shareholders pursuant to the Right of First Refusal) by
(ii) a fraction, the numerator of which is the number of Shares owned by such Participating Shareholder immediately before consummation of the proposed transfer (including any shares that such Participating Shareholder has agreed to purchase
pursuant to the Right of First Refusal) and the denominator of which is the total number of Shares owned, in the aggregate, by all Participating Shareholders immediately prior to the consummation of the proposed transfer (including any shares that
all Participating Shareholders have collectively agreed to purchase pursuant to the Right of First Refusal), plus the number of Transfer Shares held by the Selling Shareholder. To the extent one (1) or more of the Participating Shareholders
exercise such right of participation in accordance with the terms and conditions set forth herein, the number of Transfer Shares that the Selling Shareholder may sell in the proposed transfer shall be correspondingly reduced. 

 

	7.3	 The Participating Shareholders and the Selling Shareholder agree that the terms and conditions of any
proposed transfer in accordance with this Clause 7 will be memorialized in, and governed by, a written purchase and sale agreement with the Buyer (the “Purchase and Sale Agreement”) with customary terms and provisions for
such a transaction, and the Participating Shareholders and the Selling Shareholder further covenant and agree to enter into such Purchase and Sale Agreement as a condition precedent to any sale or other transfer in accordance with this Clause
7. 

  

	7.4	 Subject to Clause 7.5, the aggregate consideration payable to the Participating Shareholder and the
Selling Shareholder shall be allocated based on the number of Shares sold to the Buyer by each Participating Shareholder and the Selling Shareholder as provided in Clause 7.2. 

 

	7.5	 In the event that the proposed transfer constitutes a change of Control, the terms of the Purchase and Sale
Agreement shall provide that the aggregate consideration from such transfer shall be allocated to the Participating Shareholders and the Selling Shareholder as if (A) such transfer were a Deemed Liquidation Event, and (B) the Shares sold
in accordance with the Purchase and Sale Agreement were the only Shares outstanding. 

  

	7.6	 Notwithstanding Clause 7.3 above, if any Buyer refuse(s) to purchase Shares subject to the Right of
Co-Sale from any Participating Shareholder(s) or upon the failure to negotiate in good faith a Purchase and Sale Agreement reasonably satisfactory to the Participating Shareholders, no Selling Shareholder may sell any Transfer Shares to such Buyer
unless and until, simultaneously with such sale, such Selling Shareholder purchases all Shares subject to the Right of Co-Sale from such Participating Shareholder(s) on the same terms and conditions (including the proposed purchase price) as set
forth in the proposed notice and as provided in Clause 7.4. Any such shares transferred to the Selling Shareholder will be transferred to the Buyer against payment therefor in consummation of the sale of the Transfer Shares pursuant to the
terms and conditions specified in the transfer notice, and the Selling Shareholder shall concurrently therewith remit or direct payment to each such Participating Shareholder the portion of the aggregate consideration to which each such
Participating Shareholder is entitled by reason of its participation in such sale as provided in this Clause 7.6. 

  
 22 

	7.7	 If any proposed transfer is not consummated within forty-five (45) days after receipt of the Transfer
Notice by the Company, the Selling Shareholder(s) may not sell any Transfer Shares unless they first comply in full with each provision of this Clause 7. 

 

	7.8	 Each Party acknowledges and agrees that any breach of this Agreement would result in substantial harm to the
other Parties for which monetary damages alone could not adequately compensate. Therefore, the Parties unconditionally and irrevocably agree that any non-breaching Party shall be entitled to be reimbursed for any Losses and other remedies available
at law (including, without limitation, seeking specific performance or the rescission of purchases, sales and other transfers of Transfer Shares not made in strict compliance with this Agreement). 

 

	7.9	 If any Selling Shareholder purports to sell any Transfer Shares in contravention of the Right of Co-Sale (a
“Prohibited Transfer”), each Participating Shareholder who desires to exercise its Right of Co-Sale under Clause 7.1 may, in addition to such remedies as may be available by law or hereunder, require such Selling Shareholder
to purchase from such Shareholder the type and number of Shares that such Participating Shareholder would have been entitled to sell to the Buyer had the Prohibited Transfer been effected in compliance with the terms of Clause 7.1. The sale
will be made on the same terms, including as provided in Clause 7.4 and subject to the same conditions as would have applied had the Selling Shareholder not made the Prohibited Transfer, except that the sale (including the delivery of the
purchase price) must be made within ninety (90) days after the Participating Shareholders learns of the Prohibited Transfer, as opposed to the timeframe that would otherwise apply. Such Selling Shareholder shall also reimburse each
Participating Shareholder for any and all reasonable and documented out-of-pocket fees and expenses, including reasonable legal fees and expenses, incurred pursuant to the exercise or the attempted exercise of the Participating Shareholder’s
rights under Clause 7. 

  

	7.10	 Notwithstanding the foregoing or anything to the contrary herein, the foregoing provisions shall not apply
(a) in the case of a Selling Shareholder that is an entity, upon a transfer by such Selling Shareholder to its shareholders, members, partners, affiliated funds (or funds affiliated with such Selling Stockholder’s Affiliates) or other
equity holders, (b) to a repurchase of Transfer Shares from a Selling Shareholder by the Company at a price no greater than that originally paid by such Selling Shareholder for such Transfer Shares and pursuant to an agreement containing
vesting and/or repurchase provisions approved by a majority of the Supervisory Board, or (c) in the case of a Selling Shareholder that is a natural person, upon a transfer of Transfer Shares by such Selling Shareholder made for bona fide estate
planning purposes, either during his or her lifetime or on death by will or intestacy to his or her spouse, child (natural or adopted), or any other direct lineal descendant of such Selling Shareholder (or his or her spouse) (all of the foregoing
collectively referred to as “family members”), or any other relative/person approved by the Supervisory Board, or any custodian or trustee of any trust, partnership or limited liability company for the benefit of, or the ownership
interests of which are owned wholly by such Selling Shareholder or any such family members; provided that in the case of clause(s) (a) or (c), the Selling Shareholder shall deliver prior written notice to the Company and the Shareholders
of such pledge, gift or transfer and such Transfer Shares shall at all times remain subject to the terms and restrictions set forth in this Agreement and such transferee shall, as a condition to such issuance, deliver a signature page to a Deed of
Accession in the form attached hereto as Schedule 2 as confirmation that such transferee shall be bound by all the terms and conditions of this Agreement as a Selling Shareholder (but only with respect to the Shares so transferred to the
transferee), including the obligations of a Shareholder with respect to proposed transfers of such Transfer Shares pursuant to Clause 7. 

  
 23 

	7.11	 Notwithstanding the foregoing or anything to the contrary herein, the provisions of this Clause 7 shall not
apply to the (i) sale of any Shares to the public in an IPO, (ii) in connection with a Sale of the Company, or (iii) in connection with a Permitted Transfer. 

 

	8.	 DRAG ALONG 

 

	8.1	 In the event that each of Athyrium, Norgine, and Korys (together, the “Selling Investors”)
approve a Sale of the Company in writing, specifying that this Clause 8 shall apply to such transaction, then each of the Company, Athyrium, Norgine, and Korys hereby agrees: 

 

	 	(a)	 if such transaction requires Shareholder approval, with respect to all Shares that such Shareholder owns or
over which such Shareholder otherwise exercises voting power, to vote (in person, by proxy or by action by written consent, as applicable) all Shares in favour of, and adopt, such Sale of the Company (together with any related amendment to the
Articles required in order to implement such Sale of the Company) and to vote in opposition to any and all other proposals that could delay or impair the ability of the Company to consummate such Sale of the Company; 

 

	 	(b)	 if such transaction is a Share Sale, to sell the same proportion of shares of share capital of the Company
beneficially held by such Shareholder as is being sold by the Selling Investors to the Person to whom the Selling Investors propose to sell their Shares, and, except as permitted in Clause 8.2 below, on the same terms and conditions as the
Selling Investors; 

  

	 	(c)	 to execute and deliver all related documentation and take such other action in support of the Sale of the
Company as shall reasonably be requested by the Company or the Selling Investors in order to carry out the terms and provision of this Clause 8, including, without limitation, executing and delivering instruments of conveyance and transfer,
and any purchase agreement, merger agreement, indemnity agreement, escrow agreement, consent, waiver, governmental filing, share certificates duly endorsed for transfer (free and clear of impermissible liens, claims and encumbrances), and any
similar or related documents; 

  

	 	(d)	 not to deposit, and to cause their Affiliates not to deposit, except as provided in this Agreement, any
Shares of the Company owned by such party or Affiliate in a voting trust or subject any Shares to any arrangement or agreement with respect to the voting of such Shares, unless specifically requested to do so by the acquiror in connection with the
Sale of the Company; 

  

	 	(e)	 to refrain from exercising any dissenters’ rights or rights of appraisal under applicable law at any
time with respect to such Sale of the Company; 

  

	 	(f)	 if the consideration to be paid in exchange for the Shares pursuant to this Clause 8 includes any
securities and due receipt thereof by any Shareholder would require under applicable law (x) the registration or qualification of such securities or of any person as a broker or dealer or agent with respect to such securities; or (y) the
provision to any Shareholder of any information other than such information as a prudent issuer would generally furnish in an offering made solely to “accredited investors” as defined in Regulation D promulgated under the Securities Act,
the Company may cause to be paid to any such Shareholder in lieu thereof, against surrender of the Shares which would have otherwise been sold by such Shareholder, an amount in cash equal to the fair value (as determined in good faith by the
Company) of the securities which such Shareholder would otherwise receive as of the date of the issuance of such securities in exchange for the Shares; and 

  
 24 

	 	(g)	 in the event that the Selling Investors, in connection with such Sale of the Company, appoint a Shareholder
representative (the “Shareholder Representative”) with respect to matters affecting the Shareholders under the applicable definitive transaction agreements following consummation of such Sale of the Company, (x) to consent to
(i) the appointment of such Shareholder Representative, (ii) the establishment of any applicable escrow, expense or similar fund in connection with any indemnification or similar obligations, and (iii) the payment of such
Shareholder’s pro rata portion (on an as converted to Ordinary Shares basis) (from the applicable escrow or expense fund or otherwise) of any and all reasonable fees and expenses to such Shareholder Representative in connection with such
Shareholder Representative’s services and duties in connection with such Sale of the Company and its related service as the representative of the Shareholders, and (y) not to assert any claim or commence any suit against the Shareholder
Representative or any other Shareholder with respect to any action or inaction taken or failed to be taken by the Shareholder Representative in connection with its service as the Shareholder Representative, absent fraud or willful misconduct.

  

	8.2	 Notwithstanding the foregoing, neither Athyrium nor a Major Shareholder will be required to comply with
Clause 8.1 above in connection with any proposed Sale of the Company (the “Proposed Sale”), and, for the avoidance of doubt, will not be required to comply with Clause 8.1 above in the event of a Sale of the Company
approved pursuant to Section 8.8 of the Shareholders’ Agreement, unless: 

  

	 	(a)	 any representations and warranties to be made by such Shareholder in connection with the Proposed Sale are
limited to representations and warranties related to authority, ownership and the ability to convey title to such Shares, including representations and warranties that (i) the Shareholder holds all right, title and interest in and to the Shares
such Shareholder purports to hold, free and clear of all liens and encumbrances, (ii) the obligations of the Shareholder in connection with the transaction have been duly authorized, if applicable, (iii) the documents to be entered into by
the Shareholder have been duly executed by the Shareholder and delivered to the acquirer and are enforceable against the Shareholder in accordance with their respective terms; and (iv) neither the execution and delivery of documents to be
entered into in connection with the transaction, nor the performance of the Shareholder’s obligations thereunder, will cause a breach or violation of the terms of any agreement, law or judgment, order or decree of any court or governmental
agency; 

  

	 	(b)	 the Shareholder shall not be liable for the inaccuracy of any representation or warranty made by any other
person in connection with the Proposed Sale, other than the Company (except to the extent that funds may be paid out of an escrow established to cover breach of representations, warranties and covenants of the Company as well as breach by any
Shareholder of any of identical representations, warranties and covenants provided by all Shareholders); 

  

	 	(c)	 the liability for indemnification, if any, of such Shareholder in the Proposed Sale and for the inaccuracy
of any representations and warranties made by the Company or its Shareholders in connection with such Proposed Sale, is several and not joint with any other person (except to the extent that funds may be paid out of an escrow established to cover
breach of representations, warranties and covenants of the Company as well as breach by any Shareholder of any of identical representations, warranties and covenants provided by all Shareholders), and is pro rata (on an as-converted to Ordinary
Share basis) in proportion to, and does not exceed, the 

  
 25 

	 	 
amount of consideration paid to such Shareholder in connection with such Proposed Sale; and 

  

	 	(d)	 upon the consummation of the Proposed Sale (i) each holder of each class or series of the
Company’s share capital will receive the same form of consideration for their shares of such class or series as is received by other holders in respect of their shares of such same class or series of share capital, (ii) each holder of a
series of Preference Shares will receive the same amount of consideration per share of such series of Preference Shares as is received by other holders in respect of their shares of such same series, (iii) each holder of Ordinary Shares will
receive the same amount of consideration per share of Ordinary Shares as is received by other holders in respect of their shares of Ordinary Shares, and (iv) unless the holders of at least two-thirds of the Initially Issued Preference Shares
elect to receive a lesser amount by written notice given to the Company at least ten (10) days prior to the effective date of any such Proposed Sale, the aggregate consideration receivable by all holders of the Preference Shares and Ordinary
Shares shall be allocated among the holders of Preference Shares and Ordinary Shares on the basis of the relative liquidation preferences to which the holders of each respective series of Preference Shares and the holders of Ordinary Shares are
entitled in a Deemed Liquidation Event (assuming for this purpose that the Proposed Sale is a Deemed Liquidation Event) in accordance with the Articles in effect immediately prior to the Proposed Sale; provided, however,
that, notwithstanding the foregoing, if the consideration to be paid in exchange for the Shares pursuant to this Clause 8.2(d) includes any securities and due receipt thereof by any Shareholder would require under applicable law
(x) the registration or qualification of such securities or of any person as a broker or dealer or agent with respect to such securities; or (y) the provision to any Shareholder of any information other than such information as a prudent
issuer would generally furnish in an offering made solely to “accredited investors” as defined in Regulation D promulgated under the Securities Act, the Company may cause to be paid to any such Shareholder in lieu thereof, against
surrender of the Shares which would have otherwise been sold by such Shareholder, an amount in cash equal to the fair value (as determined in good faith by the Company) of the securities which such Shareholder would otherwise receive as of the date
of the issuance of such securities in exchange for the Shares. 

  

	8.3	 No Selling Investor shall be a party to, or approve, any Share Sale unless all Selling Investors are allowed
to participate in such transaction and the consideration received pursuant to such transaction is allocated among the parties to such Share Sale in the manner specified in the Articles in effect immediately prior to the Share Sale (as if such
transaction were a Deemed Liquidation Event). 

  

	9.	 TERMINATION 

 

	9.1	 This Agreement shall terminate with immediate effect upon the earlier of the written consent of:

  

	 	(a)	 holders of a majority of the Initially Issued Preference Shares (or Ordinary Shares issued upon conversion
of the Initially Issued Preference Shares); and 

  

	 	(b)	 Athyrium and the holders of a majority of the Shares held by the other Parties to this Agreement.

  

	9.2	 Upon termination of this Agreement, all rights and obligations of the Parties under this Agreement shall end
except for this Clause 9 and Clauses 1 (Definitions and 

  
 26 

	 	 
Interpretations), 10.13 (Governing Law) and 10.14 (Jurisdiction), which will remain in full force and effect. 

 

	9.3	 Prior to termination of this Agreement, the obligations under Clauses 2, 3, 4,
5, 7, and 8, of this Agreement shall terminate upon Admission. 

  

	10.	 GENERAL PROVISIONS 

 

	10.1	 Most Favoured Nations 

 

	 	(a)	 Notwithstanding any other provision of this Agreement, if any Shareholder contractually acquires a
shareholder-related right or benefit that is contemplated by or the subject of Clauses 3.5, 3.6, 4.1, or 5 of this Agreement and is, in the good-faith and reasonable opinion of Athyrium, more favourable in comparison to
such corresponding right or benefit established in favour of Athyrium under this Agreement, then the Company shall, insofar as it is capable under Applicable Law, offer such right or benefit to Athyrium, including by facilitating any necessary
corporate approvals in connection therewith; provided, that, for the avoidance of doubt, Athyrium’s right under this provision shall not extend to shareholder-related rights or benefits that are contemplated by the Articles (as
may be amended in a manner permitted by this Agreement), including without limitation the ranking of classes of capital stock of the Company in respect of the distribution of assets on the liquidation, dissolution or winding up of the Company, the
payment of dividends or rights of redemption. 

  

	 	(b)	 Athyrium’s right under Clause 10.1(a) shall lapse in its entirety upon it failing to purchase
its full pre-emptive entitlement under the Articles or Clause 4.2(a), as applicable, in connection with a bona fide debt or equity financing of the Company, except where Athyrium, Norgine, and Korys each agree to waive all pre-emptive
entitlements under the Articles and Clause 4.2 in connection with such financing. 

  

	10.2	 Further assurance 

Each of the Parties shall sign all such further documents and shall perform all further acts as reasonably necessary for the
purpose of satisfying their respective obligations under this Agreement, including exercising voting rights, convening meetings and giving all waivers and consents and the passing of all resolutions reasonably required to ensure that full effect is
given to the provisions of this Agreement. 
  

	10.3	 Notices 

All notices, consents, waivers and other communications in connection with this Agreement shall be in writing in English and
delivered by hand or sent by registered mail, express courier or email to the appropriate addresses set out on such Party’s signature page hereto, or to such addresses as a Party may give notice to the other Party from time to time. A notice
shall be effective upon receipt and shall be deemed to have been received (i) if delivered by hand, registered mail or express courier, at the time of delivery, or (ii) if delivered by email, at the time of successful transmission. 

 

	10.4	 Accession 

  

	 	(a)	 Athyrium shall procure that any member of the Athyrium Group that acquires any Shares executes a Deed of
Accession, whereupon such member of the Athyrium Group shall be entitled to the rights and benefits and be subject to the obligations 

  
 27 

	 	 
of Athyrium under this Agreement. The Company agrees to countersign any such Deed of Accession upon request by Athyrium. 

 

	 	(b)	 Any Person who becomes a holder of Preference Shares following the date hereof may become a party to this
Agreement by execution of a Deed of Accession in the form attached hereto as Schedule 2. 

  

	10.5	 Entire agreement 

Except for the Shareholders’ Agreement (as may be amended in accordance with the terms of this Agreement) and the
Articles, this Agreement supersedes any preceding or concurrent oral or written agreements between the Parties relating to the subject matter of this Agreement and no Party shall have any right or remedy against any other Party arising out of or in
connection with any such preceding or concurrent agreements unless stated otherwise herein. 
  

	10.6	 Third-Party Beneficiaries 

To the extent any provision in this Agreement is given for the benefit of a Shareholder that is not a party to this Agreement,
such provision constitutes an irrevocable third-party stipulation for no consideration (onherroepelijk derdenbeding om niet) for the benefit of such Shareholder. 
  

	10.7	 Amendment 

This Agreement may only be amended by the written agreement or the consent of each of the Company, Athyrium, Norgine, Korys,
and any additional Person that becomes a Party after the date hereof. 
  

	10.8	 Assignment 

None of the Parties may assign or procure the assumption of its rights and obligations under this Agreement, either in whole or
in part, to any other Person without the prior written consent of (i) the Company, not to be unreasonably withheld, and (ii) Parties holding a majority of the Shares (on an as-converted to Ordinary Share basis) held by the Parties to this
Agreement; provided, however, that Athyrium may assign its rights and obligations, in whole or in part, to any Affiliate of Athyrium. 
  

	10.9	 No recourse 

Each of Athyrium, Norgine, and Korys is organised for the purpose of investing in the broader healthcare and life sciences
industry. Any claim against any such Shareholder is against it as such, and not against any participants in it who, accordingly, are not liable for these claims, and recourse for such claims shall be limited to the assets held such Shareholder. 

 

	10.10	 Counterparts 

This Agreement may be executed in any number of counterparts. 

 

	10.11	 Partial invalidity 

The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any
other provision of this Agreement. Any such invalid or 

  
 28 

 
unenforceable provision shall be replaced or be deemed to be replaced with a provision that is valid and enforceable and reflects as closely as possible the intent of the invalid or unenforceable
provision. 
  

	10.12	 No annulment or dissolution 

Unless explicitly stated otherwise in this Agreement and to the extent permitted by Applicable Law, the Parties waive their
rights under sections 6:228, 6:230 and 6:265 of the Civil Code, if any, to annul (vernietigen), dissolve (ontbinden) or propose the amendment of this Agreement (in whole or in part), and/or to request the annulment
(vernietiging), dissolution (ontbinding) or amendment of this Agreement. 
  

	10.13	 Governing law 

This Agreement is governed by the laws of the Netherlands. 

 

	10.14	 Jurisdiction 

Subject to Clause 10.14.9, all disputes arising in connection with this Agreement, or any agreements resulting
therefrom, shall, unless the relevant agreement provides otherwise, be settled in accordance with the arbitration rules (the “Rules”) of the Netherlands Arbitration Institute (Nederlands Arbitrage Instituut)
(“NAI”) and: 
 10.14.1 the arbitral tribunal shall be composed of three arbitrators appointed in accordance
with the Rules who all have a Dutch law degree or are admitted to practice Dutch law; 
 10.14.2 the place of arbitration
will be Amsterdam, the Netherlands; 
 10.14.3 the language of the proceedings will be English; 

10.14.4 the arbitrators will decide according to the rules of law (regelen des rechts); 

10.14.5 the International Bar Association (IBA) Rules on the Taking of Evidence in International Commercial Arbitration shall
not be applicable; 
 10.14.6 the arbitral award will be final and binding; 

10.14.7 each Party shall give notice to the administrator of the NAI, within one calendar month following receipt of the
arbitral award, that the Parties object to the publication in order to ensure that the arbitral award shall not be published; and 

10.14.8 the proceedings shall not be consolidated with other arbitral proceedings pursuant to section 1046 of the Dutch Code of
Civil Procedure (Wetboek van Burgerlijke Rechtsvordering) or section 39 of the Rules. 
 provided, that the
Parties will not be precluded from applying for injunctive relief in summary proceedings (kort geding) before any competent court in the Netherlands. 

[remainder of the page intentionally left blank] 

  
 29 

 THUS AGREED AND SIGNED ON THE DATE FIRST WRITTEN ABOVE COMPANY 

 

													
	 AGENDIA N.V.

					
	 By
	 	 /s/ Mark Straley
	 		 	 By:
	 	 /s/ Kurt Becker

		 	 Name:
	 	 Mark Straley
	 		 		 	 Name:
	 	 Kurt Becker

		 	 Title:
	 	 Managing Director
	 		 		 	 Title:
	 	 Managing Director

 Address for Notice: 

Name: Agendia N. V. 
 Attention:
Mark Straley, Managing Director 
 Address: Science Park 406, 1098 XH 

Amsterdam, the Netherlands 

Email: mark.straley@agendia.com 

and 
 Name: Agendia N.V. 

Attention: Kurt Becker, Managing Director 

Address: Science Park 406, 1098 XH 

Amsterdam, the Netherlands 

Email: kurt.becker@agendia.com 

with a copy (which shall not constitute notice) to: 

Name: Stibbe N.V. 
 Attention:
Pieter Schutte 
 Address: Beethovenplein 10, 1077 WM, 

Amsterdam. the Netherlands 

Email: pieter.schutte@stibbe.com 

  
 SIGNATURE
PAGE TO 
 RELATIONSHIP AGREEMENT 

 THUS AGREED AND SIGNED ON THE DATE FIRST WRITTEN ABOVE 

ATHYRIUM 
 ATHYRIUM OPPORTUNITIES III
ACQUISITION 2 LP 
 By: ATHYRIUM OPPORTUNITIES ASSOCIATES III 

LP, its General Partner 
  

			
	
                       
 
	 	 By: ATHYRIUM OPPORTUNITIES ASSOCIATES III GP LLC, the General Partner of Athyrium Opportunities Associates III
LP

  

					
		
	 By:
	 	 /s/ Andrew Hyman

		 	 Name:
	 	 Andrew Hyman

		 	 Title:
	 	 Authorized Signatory

 Address for Notice: 

Name: c/o Athyrium Capital Management, LP 

Attention: Sam Helfaer 
 Address:

 530 Fifth Avenue, Floor 25 

New York, NY 10036 

Telephone: (646) 755-30l0 

Email : SHelfaer@athyrium.com; AOF3@athyrium.com; and AHyman@athyrium.com 

with a copy (which shall not constitute notice) to: 

Name: Hogan Lovells US LLP 

Attention: William Intner 

Address: 
 100
International Drive 
 Suite 2000 

Baltimore, MD 21202 

Email : william.intner@hoganlovells.com 

  

SIGNATURE PAGE TO 

RELATIONSHIP AGREEMENT 

 THUS AGREED AND SIGNED ON THE DATE FIRST WRITTEN ABOVE 

NORGINE B.V. 
  

									
	 NORGINE B.V.
	 	
				
	 By:
	 	 /s/ Peter Stein
	 	         By:
	 	
                  
   

		 	 Name:
	 	 Peter Stein
	 		 	 Name:

		 	 Title:
	 	 Director
	 		 	 Title:

 Address for Notice: 

Name: 
 Attention: 

Address: 
 Email: 

with a copy (which shall not constitute notice) to: 

Name: 
 Attention: 

Address: 
 Email: 

NORGINE VENTURES B.V. 
  

									
	 NORGINE VENTURES B.V.
	 		 	
				
	 By:
	 	 /s/ Peter Stein
	 	         By:
	 	
                  
   

		 	 Name:
	 	 Peter Stein
	 		 	 Name:

		 	 Title:
	 	 Director
	 		 	 Title:

 Name: 

Attention: 
 Address: 

Email: 
 with a copy (which shall
not constitute notice) to: 
 Name: 

Attention: 
 Address: 

Email: 

  

SIGNATURE PAGE TO 

RELATIONSHIP AGREEMENT 

 THUS AGREED AND SIGNED ON THE DATE FIRST WRITTEN ABOVE 

KORYS 
  

											
	 KORYS INVESTMENTS NV
	 		 		 		 	
					
	 By:
	 	 /s/ Sofie Gabriëls
	 		 	 By:
	 	 /s/ Piet Colruyt

	 Name:
	 	 Sofie Gabriëls
	 		 		 	 Name:
	 	 Plet Colruyt

	 Title:
	 	 Director
	 		 		 	 Title:
	 	 Bestuurder

  

			
	 Address for Notice:

		
	 Name:
	  	 Korys Investments NV

	 Attention:
	  	 Dries Crevits, Executive Director

	 Address:
	  	 Guido Gezellestraat 126, 1654 Huizingen, Belgium

	 Email:
	  	 Dries.Crevits@Korys.BE

 with a copy (which shall not constitute notice) to: 

 

			
	 Name:
	  	 Korys Investments NV

	 Attention:
	  	 Sofie Gabriëls, CFO

	 Address:
	  	 Guido Gezellestraat 126, 1654 Huizingen, Belgium

	 Email:
	  	 Sofie.Gabriëls@Korys.BE

  
 SIGNATURE
PAGE TO 
 RELATIONSHIP AGREEMENT 

 SCHEDULE 1 (DEED OF ACCESSION) 

THIS DEED OF ACCESSION is made on [●] 

BETWEEN: 
  

	(1)	 AGENDIA N.V., a public company with limited liability (naamloze vennootschap) incorporated
under the laws of the Netherlands with its corporate seat in Amsterdam, the Netherlands, registered with the trade register of the Chamber of Commerce with number 34185452 (the “Company”); and 

 

	(2)	 [●] (the “Acceding Shareholder”).  

WHEREAS: 
 The Company and
certain of its shareholders are parties to a relationship agreement dated 24 July 2018 (the “Relationship Agreement”). 

The Acceding Shareholder is or will become a shareholder of the Company and wishes to enter into this deed pursuant to
Clause Error! Reference source not found. of the Relationship Agreement 
 THIS DEED WITNESSES as follows: 

 

	(3)	 Capitalised terms used in this Deed shall have the meanings ascribed to them in the Relationship Agreement,
unless otherwise defined in this Deed. 

  

	(4)	 The Acceding Shareholder confirms that it has been provided with a copy of the Relationship Agreement.

  

	(5)	 The Acceding Shareholder hereby undertakes to and covenants with the Parties to comply with the provisions
of, and to perform all the obligations in, the Relationship Agreement in so far as they are to be observed and performed by the holders of the Preference Shares. The Parties agree that the Acceding Shareholder will be entitled to all the rights and
benefits and be subject to all the obligations of applicable to parties to the Relationship Agreement. 

  

	(6)	 This Deed is governed by and shall be construed in accordance with the laws of the Netherlands.

  

	(7)	 Jurisdiction 

Subject to Clause (5)(i), all disputes arising in connection with this Deed, or any agreements resulting therefrom,
shall, unless the relevant agreement provides otherwise, be settled in accordance with the arbitration rules (the “Rules”) of the Netherlands Arbitration Institute (Nederlands Arbitrage Instituut) (“NAI”)
and: 
  

	 	(a)	 the arbitral tribunal shall be composed of three arbitrators appointed in accordance with the Rules who all
have a Dutch law degree or are admitted to practice Dutch law; 

  

	 	(b)	 the place of arbitration will be Amsterdam, the Netherlands; 

 

	 	(c)	 the language of the proceedings will be English; 

	 	(d)	 the arbitrators will decide according to the rules of law (regelen des rechts);

  

	 	(e)	 the International Bar Association (IBA) Rules on the Taking of Evidence in International Commercial
Arbitration shall not be applicable; 

  

	 	(f)	 the arbitral award will be final and binding; 

 

	 	(g)	 each party hereto shall give notice to the administrator of the NAI, within one calendar month following
receipt of the arbitral award, that the parties hereto object to the publication in order to ensure that the arbitral award shall not be published; and 

  

	 	(h)	 the proceedings shall not be consolidated with other arbitral proceedings pursuant to section 1046 of the
Dutch Code of Civil Procedure (Wetboek van Burgerlijke Rechtsvordering) or section 39 of the Rules. 

provided, that the parties hereto will not be precluded from applying for injunctive relief in summary proceedings
(kort geding) before any competent court in the Netherlands. 
 [remainder of the page intentionally left blank] 

 THUS AGREED AND SIGNED ON THE DATE FIRST WRITTEN ABOVE 

COMPANY 
  

									
	AGENDIA N.V.
					
	 By:
	 	
                  
   
	 		 	 By:
	 	
                  
   

		 	 Name:
	 		 		 	 Name:

		 	 Title:
	 		 		 	 Title:

 ACCEDING SHAREHOLDER 

			
	
	 [●]

		
	 By:
	 	
                  
   

		 	 Name:

		 	 Title:EX-4.2

 Exhibit 4.2 

DATED 10 January 2013 

THE SHAREHOLDERS OF AGENDIA N.V. 

and 
 AGENDIA N.V. 

 
  

AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT 

REGARDING 
 AGENDIA N.V.

  
  

 CONTENTS 
  

							
	Clause	 	 	  	Page	 
			
	 1.
	 	Definitions	  	 	5	 
			
	 2.
	 	Supervisory Board	  	 	9	 
			
	 3.
	 	Board Of Management	  	 	11	 
			
	 4.
	 	Decision-Making	  	 	12	 
			
	 5.
	 	Financial Information And Accounting And Capitalisation Table	  	 	12	 
			
	 6.
	 	Listing Or Sale	  	 	13	 
			
	 7.
	 	Waiver Anti Dilution Protection	  	 	14	 
			
	 8.
	 	Transfers Of Shares	  	 	14	 
			
	 9.
	 	Registration Rights	  	 	16	 
			
	 10.
	 	Restrictive Covenants	  	 	16	 
			
	 11.
	 	Covenants	  	 	17	 
			
	 12.
	 	Confidentiality	  	 	18	 
			
	 13.
	 	Notices And Other Announcements To Parties Hereto	  	 	19	 
			
	 14.
	 	Partial Invalidity	  	 	24	 
			
	 15.
	 	Waiver Of Right To Dissolution	  	 	24	 
			
	 16.
	 	Miscellaneous Provisions	  	 	24	 
			
	 17.
	 	Applicable Law And Choice Of Forum	  	 	25	 

 Exhibits 
  

			
	1.	  	Deed of Adherence
		
	2.	  	Decision Making
		
	3.	  	Heads of Agreement and SFN Side Letter dated 12 August 2003 as amended by the Deed of Issue dated 28 August 2009
		
	4.	  	Capitalisation Table

 SHAREHOLDERS’ AGREEMENT 

THIS AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT is made as of 10 January 2013 BY: 

  
 - 1 - 

	(1)	 GILDE EUROPE FOOD & AGRIBUSINESS FUND B.V., a private limited liability company incorporated
and existing under the laws of The Netherlands, having its registered office at Utrecht and its principal place of business at Newtonlaan 91, 3584 BP Utrecht, The Netherlands and registered at the commercial register at Utrecht with registration
number 30153093 (“GILDE”); 

  

	(2)	 THE GLOBAL LIFE SCIENCE VENTURES FONDS II GMBH & CO KG, represented by its general partner THE
GLOBAL LIFE SCIENCE VENTURES GMBH, a company with limited liability (Gesellschaft mit beschrankter Haftung), incorporated and existing under the laws of Germany, having its registered office at Von-der-Tann Strasse 3, D-80539, Munich, Germany (“GLSV KG”); and 

 

	(3)	 THE GLOBAL LIFE SCIENCE VENTURES FUND II LIMITED PARTNERSHIP, represented by its general partner GLOBAL
LIFE SCIENCE VENTURES (GP) LIMITED, a company with limited liability, incorporated and existing under the laws of Guernsey, having its registered office at 1 Royal Plaza, Royal Avenue, St. Peter Port, Guernsey, GY1 2HL (“GLSV LP”);

 (GLSV KG and GLSV LP hereinafter jointly referred to as “GLSV”), and 

 

	(4)	 MATIGNON DEVELOPPEMENT 1, a “Societe par Actions Simplifiee” organized under the laws
of France with its corporate seat in Paris, France, and its principle place of business at 20, Place Vendome, 75001 Paris, France (“Matignon”); and 

 

	(5)	 FCPR AXA VENTURE FUND IV, represented by its management company AXA INVESTMENT MANAGERS PRIVATE EQUITY
EUROPE, a French societe anonyme with management and supervisory board, with a share capital of €269,447, having its registered office at 20, Place Vendome, 75001 Paris, France, registered at the commercial register under 403 201 882 RCS Paris
(“FCPR AXA”): 

 (MATIGNON and FCPR AXA hereinafter jointly referred to as “AXA”), and

  

	(6)	 VAN HERK BIOTECH B.V., a private company with limited liability, incorporated and existing under the
laws of The Netherlands, having its registered office at Rotterdam and its principal place of business at Lichtenauerlaan 32, 3062 ME Rotterdam. The Netherlands and registered at the commercial register at Rotterdam with registration number 24383361
(“Van Herk”); 

  

	(7)	 GENDI B.V., a private company with limited liability, incorporated and existing under the laws of The
Netherlands, having its registered office at Amsterdam and its principal place of business at Bijlmerplein 888, Location D.02.041, 1102MG Amsterdam, The Netherlands (“lNG”); 

 

	(8)	 VLUGTINVEST B.V., a private company with limited liability, incorporated under the laws of The
Netherlands, having its registered office at Laren and its principal place of business at Naarderstraat 50, 1251BD Laren, The Netherlands (“Vlugtinvest”): 

 

	(9)	 P.H.C.J. VAN DOORNE, born in Geldrop, The Netherlands on 13 March 1965 and residing at Herdersweg 22,
1251 ER Laren, The Netherlands (“Van Doorne”); 

  
 - 2 - 

	(10)	 B.H.R. HILTERMANN, born in Best, The Netherlands on 8 October 1947 and residing at Diepsmeerweg 32, 1749
AZ Warmenhuizen, The Netherlands (“Hiltermann”); 

  

	(11)	 C.M.G. Huijskes-van Doorne, born at Geldrop on the twenty-first day of December nineteen hundred and sixty-six and residing at Joelaan 1, 1217 GG Hilversum, The Netherlands (“Huijskes-van Doorne”); 

  

	(12)	 DEBIOINNOVATION S.A., a limited liability company incorporated and existing under the laws of
Switzerland, having its registered office at 123, chemin de 1a Glâne, 1677 Prez-vers-Siviriez, Switzerland (“Debioinnovation”); 

  

	(13)	 NORGINE B.V., a private company with limited liability incorporated and existing under the laws of The
Netherlands, having its registered office at Hogehilweg 7, 1101 CA, Amsterdam ZO, The Netherlands (“Norgine”); 

  

	(14)	 DRAM N.V., a limited liability company incorporated and existing under the laws of Belgium, having its
registered office at A. Vaucampslaan 42, 1654 Huizingen, Belgium (“Korys”); 

  

	(15)	 STICHTING VOGELGEZANG, a foundation (Stichting) incorporated and existing under the laws of The
Netherlands, having its registered office at Eisenhowerlaan 124, 2517 KM The Hague, The Netherlands (“Vogelgezang”); 

  

	(16)	 HARTWIG HOUDSTERMAATSCHAPPIJ B.V., a private company with limited liability, incorporated under the laws
of The Netherlands, having its registered office at Strawinskylaan 377, 1077 XX Amsterdam, The Netherlands (“Hartwig”); 

  

	(17)	 C. GODDARD, born in Reading, United States of America on 28 May 1959 and residing at 30 Allenby Drive,
Northport, New York 11768, United States of America (“Goddard”); 

  

	(18)	 PIETRO SCALFARO, born in Cortale, Italy on 13 May 1964 and residing at C.P. 21, Rue du Temple 14, CH-1096 Cully, Switzerland (“Scalfaro”); 

  

	(19)	 HENK BRULLEMAN, born in Amsterdam, The Netherlands on 28 November 1962 and residing at Hoge Weidelaan
20, 2275 TL Voorburg, The Netherlands (“Brulleman”); 

 (Gilde, GLSV, AXA, Van Herk, lNG, Vlugtinvest, Van Doorne,
Hiltermann, Huijskes-van Doorne, Debioinnovation, Norgine, Korys, Vogelgezang, Hartwig, Goddard. Scalfaro and Brulleman hereinafter individually referred to as “Investor” and jointly referred
to as the “Investors”) 
 AND 
  

	{20)	 STICHTING FONDSEN NEDERLANDS KANKERINSTITUUT, a foundation, incorporated and existing under the laws of
The Netherlands, having its registered office at Amsterdam, and its principal place of business at Plesmanlaan 121, 1066 ex Amsterdam, The Netherlands and registered at the commercial register at Amsterdam with registration number 41208629
(“SFN”); 

  
 - 3 - 

	(21)	 KURT SCHMIDT, born in Ohio, the United States of America on 17 March 1961 and residing at Brouwersgracht
232c, 1013 HE Amsterdam, The Netherlands (“Schmidt”); 

 AND 

 

	(22)	 R. Bernards Holding B.V., a private company with limited liability, incorporated and existing under the
laws of The Netherlands, having its registered office at Abcoude and its principal place of business at Koningsvaren 37, 1391 AD Abcoude, The Netherlands and registered at the commercial register at Utrecht with registration number 30186044
(“Bernards Holding”): 

  

	(23)	 Dr. Sixt Holding B.V., a private company with limited liability, incorporated and existing under
the laws of The Netherlands, having its registered office at Amsterdam and its principal place of business at Weissenbruchstraat 115a, 2596 GP ‘s-Gravenhage, The Netherlands and registered at the
commercial register at Amsterdam with registration number 34185388 (“Sixt Holding”); 

  

	(24)	 L. Van’t Veer Holding B.V., a private company with limited liability, incorporated and existing
under the laws of The Netherlands, having its registered office at Amsterdam and its principal place of business at Brouwersgracht 192 G, 1013 HC Amsterdam, The Netherlands and registered at the commercial register at Amsterdam with registration
number 34185127 (“Van’t Veer Holding”); 

 (Bernards Holding, Sixt Holding and Van ‘t Veer Holding hereinafter
individually referred to as “Founder” and jointly referred to as the “Founders”) 
 AND 

 

	(25)	 Agendia N.V., a limited liability company, incorporated and existing under the laws of The Netherlands,
having its registered office at Amsterdam and its principal place of business at Science Park 406, 1098 XH Amsterdam, The Netherlands and registered at the commercial register at Amsterdam with registration number 34185452 (the
“Company”). 

 (The Investors, SFN, Schmidt, the Founders and the Company hereinafter individually referred to as
“Party” and jointly referred to as the “Parties”.) 
 WHEREAS: 

 

	(A)	 The Parties have entered into that certain shareholders’ agreement, dated as of 28 August 2009 and amended
and restated as of 31 October 2010 (the “Original Shareholders’ Agreement”); 

  

	(B)	 This Shareholders’ Agreement represents and evidences an amendment to and the restatement, renewal and
replacement of the Original Shareholders’ Agreement, between the Parties and any amendments thereto or thereof; 

  

	(C)	 The Parties have entered into this Shareholders’ Agreement for the purpose of regulating their
relationship with each other and certain aspects of the affairs of, and their dealing with the Company, 

  
 - 4 - 

 NOW IT IS HEREBY AGREED AS FOLLOWS: 

 

	1.	 DEFINITIONS 

  

	1.1	 In this Shareholders’ Agreement the following words and expressions shall have the following meanings:

  

			
	“Affiliate”	  	Means any legal entity in which any of the Parties or the Company, as the case may be, owns, directly or indirectly, more than fifty percent (50%) of the voting share capital or voting rights or the like;
		
	“Annual Accounts”	  	The (consolidated) annual accounts of the Company prepared each year by the Board of Management in accordance with the provisions of Book 2, title 9, of the Dutch Civil Code and on a consistent basis subject to generally accepted
accounting principles (GAAP) in The Netherlands;
		
	“Annual Budget”	  	Has the meaning ascribed thereto in Article 5.1.1;
		
	“Articles of Association”	  	Means the Articles of Association of the Company as they read as of 10 November 2011 as amended from time to time;
		
	“Authorised Transferee”	  	Means a company under the (common) Control of an Investor, a company directly or indirectly Controlling such Investor or the management company of such Investor (the “Parent”) a company under the Control of the
Parent or sister or affiliated entity within the same group of the Investor or, any investment fund or similar entity managed by the same general partner or manager as such Investor or by another general partner or manager within the same group as
such an Investor or its general partner;
		
	“Bernards”	  	Means Rene Bernards, born in Bussum on 4 January 1953;
		
	“Board of Management”	  	Means the board of managing directors (bestuur’) of the Company;
		
	“Business Day”	  	Means any day that is not a Saturday, Sunday or official public holiday in The Netherlands and on which banks in The Netherlands are open for the transaction of business;
		
	“Buyer”	  	Has the meaning ascribed to it in Article 8.3;
		
	“Company”	  	Means Agendia N.V.;

  
 - 5 - 

			
	“Competing Business”	  	Has the meaning ascribed to it in Article 10.2.1;
		
	“Confidential Information”	  	Means all information which is used in or otherwise relates to the Company’s know-how, technology, medical, business, customers or financial or other affairs including, without limitation, information relating to:
		
		  	 (a)   the marketing of goods or services including, without limitation, customer
names and lists and other details of customers, sale targets, sale statistics, market share statistics, prices, market research reports and surveys, and advertising or other promotional materials; or

		
		  	 (b)   future projects, business development or planning, commercial
relationships and negotiations; and

		
		  	 (c)   all technical and medical information (including that comprised in
formulae; techniques, designs, specifications, drawings, components lists, manuals, instructions and catalogues) relating to the business of the Company;

		
	“Control”	  	Means the power of a company, directly or indirectly (i) to exercise more than fifty percent (50%) of the voting rights at a shareholders meeting of a company or (ii) to appoint or dismiss more than fifty percent (50%) of the
directors or the board of management of a company or (iii) to direct the management of the company through the exercise of majority votes at meetings of the board of management of such company;
		
	“Deed of Adherence”	  	Means a document, substantially in form as attached hereto as Exhibit I whereby an authorised transferee of one of the Parties agrees to be bound to the terms of this Shareholders’ Agreement;
		
	“Departure Date”	  	Has the meaning given to it in Article 10.2;
		
	“Encumbrance”	  	Means a mortgage, charge, pledge, lien, option, restriction, right of first refusal, right of pre-emption, right of usufruct (vruchtgebruik), third-party right or interest, or other encumbrance or security interest of any
kind, or another type of preferential arrangement (including a title transfer or retention arrangement) having similar effect;

  
 - 6 - 

			
	“ESOP”	  	Any Employee Stock Ownership Plan or similar employee benefit plan of the Company:
		
	“General Meeting of Shareholders”	  	Means the general meeting of all Shareholders of the Company;
		
	“Heads of Agreement”	  	Means the heads of agreement between the Company and SFN and the side letter dated 12 August 2003, as amended, attached in Exhibit 3
		
	“Intellectual Property Rights”	  	Means any and all Intellectual Property which either in whole or in part, is (i) registered, deposited, filed or applied for in the name of, or (ii) owned or acquired by or otherwise the property of the Company (either
alone or jointly with others) or (iii) used or required to be used by the Company or an Affiliate, if any;
		
	“Intellectual Property”	  	Means any and all intellectual property rights in any country or jurisdiction, including but not limited to any patents, utility models, lay-out designs (topographies) of integrated circuits,
trade secrets, know-how, industrial designs, copyrights, neighbouring rights, database rights or other rights in compilations of data, trademarks, trade names, internet domain names, plant variety rights and
any and all rights of a similar nature, either (i) now unknown, not contemplated or unforeseen, (ii) having a statutory basis or existing under equity, common law or otherwise, or (iii) whether registered, deposited, filed or not, and
including (a) any and all rights in connection with applications for or rights to apply for or acquire any and all of such rights, and (b) any and all privileges, ancillary rights and goodwill in connection with any such rights;
		
	“Investors”	  	Means Gilde, GLSV, AXA, Van Herk, ING, Vlugtinvest, Van Doome, Hitlermann, Huijskes-van Doome, Debioinnovation, Norgine, Korys, Vogelgezang, Hartwig, Goddard, Scalfaro and Brulleman, including
any successor that is an Authorised Transferee;
		
	“IPO”	  	Means an initial public offering of any Common Shares of the Company on a recognized stock exchange;
		
	“Listing”	  	The listing on an internationally recognised stock exchange of any shares in the Company;

  
 - 7 - 

			
	Agreement”	  	Has the meaning given to it in the recitals under (A);
		
	“Parties”	  	Has the meaning given to it in the heading of this Shareholders’ Agreement;
		
	“Qualified Majority of the Investors”	  	Means a majority of sixty percent (60%) of the Shares held by Investors;
		
	“Sale”	  	Means a sale of more than fifty percent (50%) of the then outstanding shares or a sale (including without limitation a merger, exchange, consolidation, demerger or the like) by the Company of any business or other assets comprising
substantially all of the Company’s businesses or assets;
		
	“Selling Shareholder”	  	Has the meaning given to it in .Article 8.3;
		
	“Shareholders’ Agreement”	  	Means this amended and restated shareholders’ agreement including the Recitals and all Schedules thereto;
		
	“Shareholders”	  	Means any holder of shares m the capital of the Company of whatever class;
		
	“Shares”	  	Means any and all shares from time to time outstanding in the share capital of the Company;
		
	“Supervisory Board”	  	Means the board of supervisory directors (road van commissarissen) of the Company from time to time;
		
	“Supervisory Director”	  	Means a member of the Supervisory Board (commissaris);
		
	“Van’t Veer”	  	Means Laura Johanna van’t Veer, born in Amsterdam on 2 March 1957.

  

					
	 1.2  The recitals and schedules from an integral part of this
Shareholders’ Agreement, and a reference to a Recital, Schedule or Article means a recital, schedule or article of this Shareholders’ Agreement.

	
	 1.3  The Parties agree that if there is a conflict between any provision
of this Shareholders’ Agreement and any provision of the Articles of Association, they shall observe the provisions of this Shareholders’ Agreement to the effect that

  

			
		 	 1.3.1  if the Articles of Association prescribe the observance of requirements that
are less stringent than the corresponding requirements set out in this Shareholders’ Agreement, the Parties shall also observe the latter requirements; and

  
 - 8 - 

			
		 	 1.3.2  if the Articles of Association prescribe the observance of requirements that
are more stringent than the corresponding requirements set out in this Shareholders’ Agreement, upon the requirements of this Shareholders’ Agreement having been satisfied the Parties shall without discretion co-operate in ensuring that
the requirements of the Articles of Association are also satisfied without delay;

		
		 	 1.3.3  if this Agreement contains provisions that are more extensive, specific or
detailed than the corresponding provisions of the Articles of Association, the Shareholders shall exercise all voting and other rights and powers available to them so as to give effect to the provisions of this Agreement where required after
compliance with the relevant provisions of the Articles of Association and shall further, in the event of a conflict between this Agreement and the Articles of Association, procure to the extent permitted by the laws of The Netherlands any amendment
to the Articles of Association required to bring them in line with the Agreement.

		
	 2.   SUPERVISORY BOARD
	 	
	
	 2.1  The Company shall have a Supervisory Board consisting of such a
number of members as determined by the General Meeting of Shareholders. The Supervisory Board shall consist of at least five members. The Shareholders agree that they shall exercise their voting rights to ensure that the Supervisory Board shall at
all times consist of:

		
		 	 2.1.1  one member, who shall be appointed on the basis of a binding nomination
submitted by Gilde;

		
		 	 2.1.2  one member, who shall be appointed on the basis of a binding nomination
submitted by Van Herk Biotech B.V.;

		
		 	 2.1.3  one member, who shall be independent from each of the Investors, SFN and the
Founders, who shall be appointed on the basis of a binding nomination submitted by Van Herk Biotech B.V.;

		
		 	 2.1.4  one member, who shall be appointed on the basis of a binding nomination
submitted by SFN;

		
		 	 2.1.5  one member, who shall be appointed on the basis of a binding nomination
submitted by ING. In case ING nominates Mr Hessel Lindenbergh, Mr Lindeobergh will act as Chairman of the Supervisory Board, always provided that the Supervisory Board may decide at any time that another person shall act as Chairman of the
Supervisory Board;

  
 - 9 - 

	 	2.1.6	 one member, who shall be appointed on the basis of a binding nomination submitted by Debioinnovation; and

  

	 	2.1.7	 one member, who shall be appointed on the basis of a binding nomination submitted by Korys.

  

	2.2	 In case Mr Lindenbergh ceases to be Chairman of the Supervisory Board, the General Meeting of Shareholders
shall either (i) resolve that the Supervisory Board shall appoint a new Chairman of the Supervisory Board from among its members 2! (ii) appoint one new member of the Supervisory Board which member will serve as the Chairman of the Supervisory
Board, always provided that any appointee pursuant to (i) or (ii) must be independent from each of the Investors, SFN and the Founders. For the avoidance of doubt, any nominee pursuant to Article 2.1 shall not be considered independent.

  

	2.3	 With respect to such appointments, the Shareholders shall vote their shares in favour of the appointment of the
first person appearing on the relevant nomination. The Parties entitled to make a nomination in terms of Article 2.1 shall consult in good faith with the others before making any nomination, but for the avoidance of doubt shall ultimately be free to
nominate any person they deem fit for the position. 

  

	2.4	 Neither any member of the Supervisory Board nor any of the persons holding any of the observers seats on behalf
of GLSV, AXA, Vlugtinvest and/or Gendi (as described in Article 2.7) may hold a position in any corporate body of a (legal), entity which directly competes with the business of the Company, as described in the Business Plan. The Parties shall
procure that each member of the Supervisory Board signs a confidentiality agreement substantially in the form as set out in Article 12.1. 

  

	2.5	 The Supervisory Board shall, unless agreed otherwise in this Shareholders’ Agreement, adopt resolutions
with an absolute majority of the votes casts. 

  

	2.6	 The Supervisory Board shall meet at least six times per year. Each Supervisory Director may call a meeting of
the Supervisory Board as and when he deems necessary, upon at least five (5) Business Days notice. The Supervisory Board may adopt resolutions without convening a meeting (in writing or by telephone) provided that all members have been
consulted and none of them has objected to this matter of decision-making. 

  

	2.7	 Parties agree that as long as each of AXA, GLSV, Vlugtinvest and Gendi hold more than a half percent (0.5%) of
the Shares, they shall each have an ‘observer seat’ in the Supervisory Board allowing them to attend in meetings of the Supervisory Board without having the right to participate in the discussions in these meetings or exercise any votes in
the Supervisory Board. Each such observer shall receive any invitations including the agenda to the meetings of the Supervisory Board and subcommittees thereof as well as all information and documents sent to the members of the Supervisory Board as
if it was a member of the Supervisory Board. If the Chairman of the Supervisory Board requests the observers to leave the meeting of the Supervisory Board for a specific item to be discussed among the members of the Supervisory Board themselves and
which request is carried by a majority of the Supervisory Board members, than the observers shall leave the meeting without hesitation. To accommodate the observers, the Company shall organize a minimum of four (4) information meetings with the
Investors, which will precede the meetings of the Supervisory Board of that day. 

  
 - 10 - 

	2.8	 The Shareholders shall vote in favour of the dismissal or suspension of a Supervisory Director appointed in
accordance with Article 2.1 and Article 2.2 only if and when such dismissal or suspension is requested by the Party at whose nomination such Supervisory Director has been appointed. 

 

	2.9	 Only independent representatives on the Supervisory Board shall be adequately compensated, to be agreed by the
Shareholders holding majority of the Shares. 

  

	2.10	 Any Supervisory Director and any board observer may disclose any information relating to the Company that he
obtains or receives in his capacity as Supervisory Director or board observer to the Investor that appointed him, provided that each Supervisory Director and each board observer will observe his fiduciary duties towards the Company, to the extent
applicable. 

  

	3.	 BOARD OF MANAGEMENT 

 

	3.1	 The Supervisory Board, by a resolution requiring an absolute majority of the votes cast in a meeting in which
all of the members of the Supervisory Board are present or represented shall have the right to make binding proposals to the General Meeting of Shareholders with respect to shareholders decisions regarding the appointment, suspension and dismissal
of members of the Board of Management. 

 The General Meeting shall adopt the necessary resolutions following a proposal of
the Supervisory Board within the meaning of Article 3.1. 
  

	3.2	 The Supervisory Board, by a resolution requiring an absolute majority of the votes cast in a meeting in which
all of the members of the Supervisory Board are present or represented, shall have the right to make binding proposals to the General Meeting of Shareholders with respect to shareholders decisions regarding the remuneration or changes in the
remuneration of the members of the Board of Management or any other conditions of employment agreements with the respective members of the Board of Management. 

The General Meeting shall adopt the necessary resolutions following a proposal of the Supervisory Board within the meaning of Article 3.2. 

 

	3.3	 The Company shall have a Board of Management responsible for the day-to-day operations of the Company. The Board of Management shall subject to Article 3.1 be appointed by the General Meeting of Shareholders and shall consist of a minimum of one and a maximum of five
managing directors. The Board of Management or any two managing directors, acting jointly, shall be authorised to represent the Company. 

  

	3.4	 In case the General Meeting of Shareholders cannot reach the majority prescribed by Part A of Exhibit 2 or in
case of a deadlock in the Supervisory Board on matters and/or decisions of the Board of Management which are subject to their prior approval in accordance with Article 4, the Board of Management shall continue the Company’s business in its
ordinary course until such time, but refrain from the matter that needs prior approval, as the relevant matter is resolved and/or prior approval has been obtained. It being understood that if the matter at hand cannot be solved within 1 month it
will be referred forthwith to an independent third party for binding advise to be rendered within 1 month after the referral was made. 

  
 - 11 - 

	3.5	 Prior to any resolution of the Supervisory Board, the Board of Management shall be heard and given the
opportunity to present its views in connection with that resolution in a meeting with the Supervisory Board. Together with the invitation, the Board of Management shall be provided with all information necessary to prepare adequately for the meeting
with the Supervisory Board. 

  

	4.	 DECISION-MAKING 

 

	4.1	 The Parties shall exercise all voting rights and other powers of control available to them in relation to the
Company (whether as shareholder, director or otherwise) to procure that the Company shall: 

  

	 	4.1.1	 refrain from taking any of the actions listed in Part A of Exhibit 2 without the prior approval of at
least 2/3 (two thirds) of the votes cast at a General Meeting of Shareholders; and 

  

	 	4.1.2	 refrain from taking any of the actions listed in Part B of Exhibit 2 without the prior approval of the
Supervisory Board. 

  

	5.	 FINANCIAL INFORMATION AND ACCOUNTING AND CAPITALISATION TABLE 

 

	 	5.1	 As long as any of the Investors is a Shareholder, the Company shall supply each of the Investors, and to the
extent requested, each of the other Shareholders, with the following information: 

  

	 	5.1.1	 not later than one month before the start of each financial year of the Company, an annual budget, split in
monthly and/or quarterly, for the Company for that financial year, including cash flow forecast and detailed notes (the “Annual Budget”); 

  

	 	5.1.2	 as soon as practicable (and in any event within six months after the end of each financial year), the audited
(consolidated) accounts of the Company for that year; 

  

	 	5.1.3	 as soon as practicable (and in any event within ten (10) Business Days after the end of each month or
quarter), the monthly and quarterly unaudited management accounts which shall consist of a balance sheet, profit and loss account, a comparison with budget, cash flow statement, cash flow forecast for the following six months and management
commentary for the Company, all on the 

  
 - 12 - 

	 	
basis of accounting principles and policies approved by the Supervisory Board, consistently applied, as well as a brief description of all major pending management issues concerning the Company.
The monthly management report will include commercial and operational information the substance and form to be agreed upon by the Board of Management and the Supervisory Board; and 

 

	 	5.1.4	 such other financial or management information as any Investor may from time to time reasonably request.

  

	5.2	 The Company shall use its best endeavours to ensure that the Investors shall at all times be able to meet such
management and personnel of the Company as may reasonably be designated by them. upon reasonable notice to the Company, for the purpose of consulting with management, obtaining information regarding the business and prospects of the Company.

  

	5.3	 Each of the Shareholders shall procure that the Company be managed and the Board of Management shall manage the
Company in accordance with the provisions of the Annual Budget as approved from time to time in accordance with this Shareholders’ Agreement and that the Company keep true and accurate accounts and records in accordance with the accounting
principals approved from time to time by the Supervisory Board and in accordance with all applicable law. 

  

	5.4	 The Company shall permit each shareholder holding more than one percent (1%) of the Shares and such persons as
it may designate, subject to the Company’s reasonable approval and the execution of a confidentiality agreement acceptable to the Company, at such shareholders’ expense, upon not less than three (3) Business Days prior notice to the
Company to visit, during normal business hours and without disruption to the Company’s business, any of the properties of the Company, examine their books (and take copies and extracts thereof), discuss the affairs, finances and accounts of the
Company with their officers and employees, and consult with the management of the Company as to their affairs, finances and accounts, all at reasonable times and upon reasonable notice and obtaining information as if it was a member of the
Supervisory Board. The information rights in this section shall also apply to Affiliates and Authorised Transferees of the Company, if any. 

  

	5.5	 Exhibit 4 contains the Capitalisation Table reflecting the shareholding of the Shareholders in the
Company as of the date of this Agreement. 

  

	6.	 LISTING OR SALE 

 

	6.1	 If a Qualified Majority of the Investors expresses in writing to be in favour of a Listing or Sale, the Company
shall use its best endeavours to ensure that all reasonable steps are taken as are required to affect such Listing or achieve such Sale. 

  

	6.2	 In the event of a Listing, or if so requested by any Investor that has supported the request referred to in
Article 6.1, the Founders, Bernards and Van ‘t Veer and each of the members of the Board of Management shall comply with any reasonable lock-up requirements imposed by the underwriters. Sixt Holding shall
comply with the same lock-up requirements as imposed by the underwriters on the Investors. 

  
 - 13 - 

	6.3	 The Investors will have the right to sell shares (upon conversion) on a pro rata basis with the other
Shareholders as part of a Listing. 

  

	6.4	 The Parties agree that in the event of a Listing or Sale: 

 

	 	6.4.1	 the Investors shall not give any warranties and/or indemnities save for a warranty as to the validity of their
title to their shares; and 

  

	 	6.4.2	 ING Bank N.V. shall be appointed as joint bookrunner for the Listing at conditions in accordance with
prevailing market practice. 

  

	7.	 WAIVER ANTI DILUTION PROTECTION 

 

	7.1	 SFN hereby explicitly waives its anti dilution protections rights as provided under the Heads of Agreement and
the Side Letter with the Company dated 12 August 2003, as amended, attached in Exhibit 3 and the other Parties accept such waiver. 

  

	8.	 TRANSFERS OF SHARES 

Free Transfers 
  

	8.1	 None of the Founders shall be permitted to transfer, encumber or otherwise dispose of any of their Shares,
unless explicitly approved by a Qualified Majority of the Investors and unless the transferee executes a Deed of Adherence. The Investors and SFN are permitted to transfer, or to agree to transfer, their Shares only to an Authorised Transferee or if
expressly permitted pursuant to this Shareholders’ Agreement and/or the Articles of Association and subject to the condition that such transferee executes a Deed of Adherence. It being understood that the Shares originally held by SFN shall
remain within the ultimate Control of NKI following such transfer to an Authorised Transferee. 

  

	8.2	 Despite anything to the contrary, any Investor may at any time transfer any of the Shares held by it to another
Investor or a wholly owned subsidiary of one of the Investors (which for the purposes of this Article 8 shall include any and all investment funds advised by any of the Investors). Despite anything to the contrary, SFN may at any time transfer any
of its Shares held by it to a wholly owned subsidiary. It being understood that the Shares originally held by SFN shall remain within the ultimate Control of NKl following such transfer. Each Shareholder hereby agrees to vote in favour of any
such transfer and to waive its right of first refusal set out in the Articles of Association with respect thereto. The transferor must procure that the transferee executes a Deed of Adherence. 

  
 - 14 - 

 Tag Along 

 

	8.3	 A Shareholder (the “Selling Shareholder”) may transfer or agree to transfer all or part of the Shares
held by it to any third party (a “Buyer”) if each of the following conditions has been satisfied (or specifically waived in writing by all Shareholders): 

 

	 	8.3.1	 arrangements must have been made with the Buyer to the effect that: 

 

	 	(a)	 the Buyer is willing also to purchase, at the same price per share and on the same conditions, the Shares from
the Investors, that an Investor wishes to sell; or 

  

	 	(b)	 all Investors are offered, on equal conditions, to participate as vendors in the sale of the total number of
Shares to be transferred to the Buyer pro rata to the number of Shares held by each of them. 

 For the avoidance of
doubt, in case the Selling Shareholders is a Founder, this article 8.3 applies only if article 8.1 has been complied with. 
  

	8.4	 Article 8.3 does not apply to any transfer by a Selling Shareholder to an Affiliate or Authorised Transferee.

  

	8.5	 The Parties agree that if the Selling Shareholder has received a bona fide offer from a Buyer to acquire
some or all of the Shares held by it, and the Selling Shareholder is willing to accept such offer and, in contemplation of doing so offers the Shares concerned for sale to the other holders of Shares in accordance with the transfer restrictions
(contained) in the Articles of Association, the price and other terms offered by the Buyer shall be considered to represent the fair market value (vrije marktwaarde) at that time of the Shares, and, subject to the transfer restrictions
(contained) in the Articles of Association, the other Shareholders shall then have the choice between: 

  

	 	8.5.1	 purchasing those Shares concerned from the Selling Shareholder themselves at such price and terms; or

  

	 	8.5.2	 confirming in writing that they do not intend to accept the offer in respect of those Shares pursuant to
Article 8.5. 

  

	8.6	 In the event that any of the Investors is in the process of liquidation or opts for a
“pre-liquidation” (in French ‘pre-liquidation’) and wants to transfer its shares to a third party, each of the other Investors shall waive its tag along rights (as described above)
by giving its prior written waiver within fifteen (15) days as from the date of request of the selling Investor, which waiver shall not be withheld unless the other Investors justify that the said third party is an industrialist active in the
health care sector, or a venture capital company directly funded at more than fifty per cent (50%) by such industrialist. The silence of the Investors during these fifteen (15) days period shall be considered an implicit waiver of their tag
along rights. 

  

	8.7	 No Shareholder shall in any event be permitted to transfer its Shares to a Buyer or such party as described in
Article 8.6 unless the Buyer or such party as described in Article 8.6 has executed a Deed of Adherence. 

  
 - 15 - 

 Drag Along 

 

	8.8	 In the event that a bona fide at arms’ length offer is made by a third party to purchase all or
part of the Shares outstanding as per such moment, which offer has been accepted by a Qualified Majority of the Investors, all holders of Shares shall be obliged to offer their Shares on the same terms and conditions of such offer. The Shareholders
shall procure that the drag along obligation shall be included in the Articles of Association. 

  

	9.	 REGISTRATION RIGHTS 

The Investors shall have customary US registration rights in the event of a listing of (or part of) the Company’s Shares
in the United States of America, including (i) one demand registration at the request of the Investors representing at least two-thirds of the Shares outstanding, (ii) customary piggy-back rights.
The Company will pay all expenses in connection with offerings in which registration rights are exercised. 
  

	10.	 RESTRICTIVE COVENANTS 

 

	10.1	 Each of the Founders, Sixt, Bernards and Van ‘t Veer covenants and undertakes towards the Company (and in
the event that the Company decides not to enforce this right, each of the Shareholders shall be entitled to so) that he/she will not at any time disclose or use for any purpose any information of a confidential nature concerning the Company or its
business, customers, financial or other affairs, and shall make every effort to prevent the use or disclosure of such confidential information, in either case except: 

 

	 	10.1.1	 to the extent required by law or any competent authority, after consultation with the Investors (to the extent
reasonably possible in the circumstances); or 

  

	 	10.12	 to the extent that such information is at the date of this Shareholders’ Agreement or hereafter becomes
public knowledge otherwise than through improper disclosure by any person. 

  

	10.2	 Each of the Founders and Sixt, Bernards and Van ‘t Veer covenants and undertakes towards the Company (and
in the event that the Company decides not to enforce this right, each of the Shareholders shall be entitled to so) that he/she will not without the prior written consent of the Supervisory Board (which it may withhold in its sole discretion without
it being required to explain its approach), at any time during his/her employment by the Company or the time he/she provides services to the Company and before the expiry of one year from the date of ceasing to be a managing director, director or
employee of the Company (the “Departure Date”), either alone or jointly with others, or as employee, adviser, manager, consultant or agent of any person or entity, directly or indirectly, do any of the following: 

 

	 	10.2.1	 within the European Union, North America or any other geographical area in which the Company conducts is
business at that time, directly or indirectly incorporate, establish or engage in any business in any way competing with the business conducted by the Company at that time (the “Competing Business”); 

  
 - 16 - 

	 	10.2.2	 acquire or hold an interest in any company or business which is itself or through any company or business
directly or indirectly controlled by it engaged in any Competing Business; 

  

	 	10.2.3	 participate in a joint-venture or other co-operative arrangement aimed
at generating Competing Business; or 

  

	 	10.2.4	 directly or indirectly carry on a business either alone or jointly with or as manager, adviser, consultant,
agent or employee of any person, whether or not the business is similar to any business of the Company, under a name including the word “AGENDIA” or other distinctive words that shall be used in the name of the Company at that time or any
name likely to be confused with a name used by the Company at the Departure Date; or 

  

	 	10.2.5	 employ or solicit the employment of any person who is, or has at any time during the two years proceeding the
Departure Date been, an employee of the Company. 

  

	10.3	 Each of the restraints in Article 10.2 shall be severable such that if any restraint is in whole or in part
unenforceable for any reason, the remaining restraints shall continue to be valid, binding and enforceable. 

  

	10.4	 Parties agree that Bernards’ and Van ‘t Veer’s employment by NKI does not conflict with the
restrictions set out in Article 10.2. 

  

	10.5	 Notwithstanding the Articles of Association and unless agreed otherwise in this Shareholders’ Agreement,
each of the Founders, Sixt, Bernards and Van ‘t Veer shall not at any time pledge or transfer any of their Shares or any shares in any of the Founders without the prior written consent of a Qualified Majority of the Investors.

  

	10.6	 If a Party fails to comply with this Article 10, such Party shall without any demand or other prior notice, owe
to the Company a penalty of two hundred fifty thousand Euro (€250,000) per such failure and twenty five thousand Euro (€25,000) per day such failure continues. The Company shall be entitled to the penalties without prejudice to its rights,
including the right to demand damages in addition to such penalties. 

  

	11.	 COVENANTS 

  

	11.1	 In the event that the Company is seeking for a loan agreement with a third party, the Company, at its sole
discretion, may first allow each of the Investors to review such loan agreement and to make an offer to the Company matching the terms of such loan agreement. 

 

	11.2	 lNG and lNG Corporate Investments Participaties B.V. shall ensure that: 

 

	 	11.2.1	 lNG Corporate Investments Participaties B.V. shall act as the sole authorised representative of lNG; and

  
 - 17 - 

	 	11.2.2	 in all cases the votes held by lNG shall be cast as a single block and not be split; and 

 

	 	11.2.3	 without the prior approval of the other Parties to this Agreement (such approval not to be unreasonably
withheld), the percentage of shares held by lNG Corporate Investments Participaties B.V. in the issued and outstanding share capital of lNG shall not decrease below 50%; and 

 

	 	11.2.4	 any transfer or issue of shares in lNG requires the prior approval (such approval not to be unreasonably
withheld) of a Qualified Majority of the Investors (not including lNG). 

 Any of the other Parties to this Agreement or
the Qualified Majority of the Investors (as the case may be) shall be deemed to have given its prior approval within the meaning of Article 11.2.3 or Article 11.2.4 (as the case may be) if it has not responded within fifteen (15) Business Days
after receipt of a request for approval by lNG. 
  

	12.	 CONFIDENTIALTIY 

 

	12.1	 Subject to Article 12.3, each Party shall treat as strictly confidential all documents and information received
or obtained as a result of entering into or performing this Shareholders’ Agreement which relates to (i) the provisions of this Shareholders’ Agreement (ii) the negotiations relating to this Shareholders’ Agreement
(iii) the subject matter of this Agreement and the transactions contemplated by this Shareholders’ Agreement or (iv) the other Parties (for the purposes of this Article 12: expressly including the Company). 

 

	12.2	 Subject to Article 12.3 from the date of this Shareholders’ Agreement until the end of a three year period
following the date on which any Party has sold all of its Shares, such Parties shall not use, divulge or transmit to any one the Confidential Information. 

  

	12.3	 Each Party may disclose information which would otherwise be Confidential Information, if and to the extent:

  

	 	(a)	 required by the law of any relevant jurisdiction; 

 

	 	(b)	 required by any securities exchange or regulatory or governmental body to which either Party is subject or
wherever situated; 

  

	 	(c)	 made to any competent court or arbitral tribunal by a party alleging a violation of this Shareholders’
Agreement; 

  

	 	(d)	 disclosed to managers, officers, employees, members of investment committees. professional advisors, auditors
and bankers of each Party, provided they agree to be bound by the confidentiality of such information; 

  

	 	(e)	 the information has come into the public domain through no fault of that Party; or 

  
 - 18 - 

	 	(f)	 the information was previously known to it or disclosed to it through no fault of that Party.

  

	12.4	 The Parties are aware that GLSV investment pursuant to the Series A Subscription Agreement in the Company is in
part refinanced by the German Kreditanstalt für Wiederaufbau (“KfW”). KfW, in return for agreeing to affect such refinance, requires under certain circumstances that its shares refinanced by KfW pro rata and held by GLSV may be
pledged. KfW’s terms and conditions also include the requirement that KfW, the German BMWi or their respective appointees pursuant to §1 BHO (German Bundeshaushaltsordnung) and the German Bundesrechnungshof are granted the right to
supervise the way funds are granted are employed. In order to comply with such requirement, the aforementioned are entitled to inspect the Company’s books and records and to generally demand information about the Company’s financial
standing. The inspection and information rights as aforesaid may also be exercised I carried out by an auditor appointed by GLSV. The costs for such auditor are to be borne by GLSV who have been refinanced by KfW. 

 

	12.5	 The Parties agree and acknowledge that ING may disclose Confidential Information to those entities directly
holding shares in its share capital, provided that prior to disclosing Confidential Information to these entities: 

  

	 	12.5.1	 the entities are informed by lNG of the confidential nature of the Confidential Information and shall agree to
keep confidential the Confidential Information in accordance with this Article 12; and 

  

	 	12.5.2	 lNG has disclosed the identity of these entities to the other Parties to this Agreement, and

  

	 	12.5.3	 the disclosure has been approved by the Company (such approval not to be unreasonably withheld)

  

	12.6	 The Parties agree and acknowledge that a Party may disclose in accordance with the provisions of this Article
12, Confidential Information (i) to those entities within its group that would fall within the definition of Authorised Transferee and to any of the investors in any of the Investors and if this disclosure is made pursuant to prescribed
reporting requirements or (ii) if such disclosure is made in connection with a transfer of its entire shareholding. The Parties further agree and acknowledge that lNG may disclose in accordance with the provisions of this Article 12,
Confidential Information to that certain party wishing to acquire fifty percent (50%) of its share capital, provided such party agrees to be bound towards the Company as to confidentiality and non-use of
Confidential Information on terms similar to this Article 12. 

  

	13.	 NOTICES AND OTHER ANNOUNCEMENTS TO PARTIES HERETO 

 

	13.1	 Any notice or other communication under or in connection with this Shareholders’ Agreement shall be in
writing and shall be delivered personally or sent by air mail prepaid recorded delivery or by facsimile or by email to the party due to receive the notice at the following addresses: 

  
 - 19 - 

 to the Investors: 

Gilde Europe Food & Agribusiness Fund B.V. 

Attn. Pieter van der Meer 

Newtonlaan 91 
 3584 BP Utrecht

 The Netherlands 
 Tel: +31
(0)30 219 25 36 
 Fax: +31 (0)30 219 25 96 

Email: vandermeer@gilde.nl 

The Global Life’ Science Ventures Fonds II GmbH & Co KG 

Represented by its general partner THE GLOBAL LIFE SCIENCE VENTURES GMBH 

Attn. Hanns-Peter Wiese 

Von-der-Tann Strasse 3 
 D-80539 Munich 
 Germany 

Tel +49 (0) 89 288 1510 
 Fax +49
(0) 89 288 15130 
 Email: HP.Wiese@glsv-vc.com 

The Global Life Science Ventures Fund II Limited Partnership 

Represented by its general partner GLOBAL LIFE SCIENCE VENTURES (GP) 

1 Royal Plaza, 
 Royal Avenue,

 St. Peter Port, Guernsey, GY1 2HL 

Email: Steve.Yates@ipes.com 

Matignon Développement 1, and FCPR AXA VENTURE FUND IV 

Each represented by its management company AXA INVESTMENT MANAGERS PRIVATE EQUITY EUROPE 

Attn. Glenn Richard 
 20 Place
Vendöme 
 75001 Paris, 

France 
 Tel: +33 (0)1 44 45 92
48/ +33 (0) 1 44 45 9274 
 Fax: +33 (0)1 44 45 93 06 

Email: glenn.richard@axa-im.com 

Van Herk Biotech B.V. 

Attn. Drs. E. Esveld 

Lichtenauerlaan 32 
 3062 ME
Rotterdam 
 The Netherlands 

Email: eesveld@vanherkgroep.nl 

  
 - 20 - 

 Gendi B.V.: 

Attn. Jan Willem Nieuwenhuize 

Bijlmerplein 888 
 Location
D.02.041 
 1102 MG Amsterdam 

The Netherlands 
 Tel: +31(0)20
652 3954 
 Fax: +31(0)20 652 3953 

Email: jan.willem.nieuwenhuize@ing.nl 

to Vlugtinvest B.V.: 

Attn. Stef Koning 
 Naarderstraat
48 
 1251BD Laren 
 The
Netherlands 
 Tel: +31 (0)35 539 3324 

Fax: +31 (0)6 539 3327 
 Email:
s.koning@breedinvest.nl 
 to P.H.C.J. Van Doorne: 

Herdersweg 22 
 1251 ER Laren 

The Netherlands 
 Email:
doorhart@euronet.nl 
 to B.H.R. Hiltermann: 

Diepsmeerweg 32 
 1749 AZ
Warmenhuizen 
 The Netherlands 

Email: boudewijnhiltermaon@hotmail.com 

C.M.G. Huijskes 
 Joelaan 1

 1217 GG Hilversum 
 The
Netherlands 
 Email: chuyskes@egeria.nl 

Debioinnovation SA 
 Attn.
T. Mauvernay 
 CP 187 
 1752 Villars-sur-Glâne 
 Switzerland 

Email: tmauveroay@debiopharm.com 

  
 - 21 - 

 With a copy to: 

Debiopharm SA 
 Attn.
Director, Service Legal Affairs 
 Chemin de Messidor 5-7 

1006 Lausanne 
 Switzerland 

Fax: +41 21 321 01 78 
 Norgine
B.V. 
 Attn. Peter Stein 

Hogehilweg 7 
 1101 CA, Amsterdam
ZO 
 The Netherlands 
 Email:
pstein@norgine.com 
 DHAM N.V. (Korys) 

Attn. Thomas Vanhoutte 
 A.
Vaucampslaan 42 
 1654 Huizingen 

Belgium 
 Email:
thomas.vanhoutte@korys.be 
 Stichting Vogelgezang 

Attn. Wiet Pot 
 Eisenhowerlaan
124 
 2517 KM The Hague 
 The
Netherlands 
 Hartwig Houdstermaatschappij B.V. 

Attn. Rob Defares 
 Strawinskylaan
377 
 1077 XX Amsterdam 
 The
Netherlands 
 C. Goddard 

30 Allenby Drive 
 Northport, New
Yolk 11768 
 United States of America 

email: c.goddard528@gmail.com 

Pietro Scalfaro 
 C.P. 21,
Rue du Temple 14 
 CH-1096 Cully 

Switzerland 
 Email:
pscalfar@bluewin.ch 

  
 - 22 - 

 Henk Brulleman 

Hoge Weidelaan 20 
 2275 TL
Voorburg 
 The Netherlands 

Email: henk@brulleman.nl 
 to SFN: 

Stichting Fondsen Nederlands Kankerinstituut 

Attention: M. Brocken 

Plesmanlaan 121 
 1066CX Amsterdam

 email: m.brocken@nki.nl 
 to Schmidt:

 Kurt Schmidt 

Brouwersgracht 232c 
 1013 HE
Amsterdam 
 email: kurt.schmidt@veresis.com 

to the Founders: 
 Dr. Sixt Holding
B.V. 
 Dr. Bernhard M. Sixt 

Jozef lsraelslaan 4B 
 2596 AP’s-Gravenhage 
 with a copy to fax +31 (0)70 324 3964 

email: Bemhard@drsixt.com 
 L.
Van 't Veer Holding B.V. 
 Dr. Laura J. van’t Veer 

Brouwersgracht 192 G 
 1013 HC
Amsterdam 
 email: l.vt.veer@nki.nl 

R. Bernards Holding B.V. 

Prof. Dr. René Bernards 

Koningsvaren 37 
 1391 AD Abcoude

 email: r.bernards@nki.nl 

  
 - 23 - 

 to the Company: 

Agendia N.V. 
 Attn. Board
of Management 
 Science Park 406 

1098 XH Amsterdam 
 The
Netherlands 
  

	13.2	 In the absence of evidence of earlier receipt, any notice or other communications shall be deemed to have been
duly given: 

  

	 	13.2.1	 if delivered personally, when left at address referred to in Article 13.1; 

 

	 	13.22	 if sent by airmail, six (6) days after posting it; and 

 

	 	13.2.3	 if sent by facsimile; one hour after its dispatch when clearly received in full. 

 

	13.3	 Either party may change its address for the pwpose of this Shareholders’ Agreement by giving notice of the
change to the other Parties pursuant to the provisions of this Article 13. 

  

	14.	 PARTIAL INVALIDITY 

In the event that one or more provisions of this Shareholders’ Agreement appear to be non-binding,
the other provisions of this Shareholders’ Agreement will continue to be effective. The Parties are obliged to replace the non-binding clauses with other clauses that are binding, in such a way that the
new clauses differ as little as possible from the non-binding clauses, taking into account the object and the pwpose of this Shareholders’ Agreement. 

 

	15.	 WAIVER OF RIGHT TO DISSOLUTION 

Parties hereto waive their right to seek dissolution (ontbinding) or annulment (vernietiging) of this Shareholders’
Agreement. 
  

	16.	 MISCELLANEOUS PROVISIONS 

 

	16.1	 This Shareholders’ Agreement shall cease to bind a Party if and when it ceases to be a Shareholder, in
both cases subject to the other Parties’ accrued rights and obligations at such time, which shall not be affected. 

  

	16.2	 The Parties shall at all times use their voting rights in the Company (and its subsidiaries, if any) and take
all other steps that are within their power to procure that full effect is given to the terms of this Shareholders’ Agreement. 

  

	16.3	 This Shareholders’ Agreement, including the provisions of this Article 16.3, may only be amended or varied
by an instrument in writing signed by or and on behalf of all the Parties from time to time. 

  

	16.4	 If any Party is obliged to pay a certain sum of money to another Party pursuant to the provisions of this
Shareholders’ Agreement and such sum is not paid on the due date of payment, interest shall accrue and be payable from the due date of the payment to the date of payment in full at a rate equal to the Dutch statutory rate applicable as per that
moment. 

  
 - 24 - 

	16.5	 For the avoidance of doubt, any of the obligations of the Founders under this Agreement are not
joint and several but pro rata their shareholding. 

  

	17.	 APPLICABLE LAW AND CHOICE OF FORUM 

 

	17.1	 The laws of The Netherlands are applicable to this Shareholders’ Agreement and any further agreements
resulting there from. 

  

	17.2	 Any disputes arising out of this Shareholders’ Agreement, including disputes conceming the existence and
validity thereof, and any further agreements resulting therefrom. which cannot be settled amicably, shall be resolved exclusively by the competent courts of Amsterdam, The Netherlands. 

This Shareholders’ Agreement is made on the day and year first written above and may be signed in counterparts which. when taken together, shall
constitute one and the same document. 
 [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK; SIGNATURE PAGE TO FOLLOW] 

  
 - 25 - 

 On behalf of GILDE EUROPE FOOD & AGRIBUSINESS FUND B.V. 

 

					
	 /s/ P.H. van der Meer
	 		  	 /s/ Marc Olivier Perret

	 By: P.H. van der Meer
 Title: Managing
Director
	 	
                          
      
 
	  	 By: Marc Olivier Perret
 Title: Managing
Director

			
	On behalf of THE GLOBAL LIFE SCIENCE VENTURES FONDS II GMBH & CO KG, represented by its General Partner The Global Life Science Ventures GmbH	 		  	On behalf of THE GLOBAL LIFE SCIENCE VENTURES FUND II LIMITED PARTNERSHIP, represented by its General Partner Global Life Science Ventures (GP) Limited
			
	 /s/ Hanns-Peter Wiese
	 		  	 /s/ Barry McCloy

	 By: Hanns-Peter Wiese
 Title:
	 		  	 By: Barry McCloy
 Title: Director

			
	On behalf of FCPI AXA PLACEMENT INNOVATION III, represented by its management company AXA Investment Managers Private Equity Europe	 		  	On behalf of FCPR AXA VENTURE FUND IV. represented by its management company AXA Investment Managers Private Equity Europe 
			
	 /s/ Alan Richard
	 		  	 /s/ Alan Richard

	 By: Alan Richard
 Title: Director
	 		  	 By: Alan Richard
 Title: Director

	
	On behalf of Stichting Fondsen Nederlands Kankerinstituut
			
	 /s/ Dick S. Bambre

By: Dick S. Bambre
 Title: Boardmember
	 		  	

  
 - 26 - 

					
	 /s/ E.G.A. Esveld
	 	                            	  	
	 By: E.G.A. Esveld
 Title:
	 		  	
			
		 		  	 On behalf of Vlugtinvest B.V.
 its managing
director
 Hoomsche Broeder B.V.

			
		 		  	 /s/ R.E. Palmer

By: R.E. Palmer
 Title: Director

			
		 		  	 /s/ S.G. Koning

By: S.G. Koning
 Title: Director

			
	 /s/ M. Hopman
	 		  	 /s/ J.W. Nieuwenhuis

	 By: M. Hopman
 Title: Director
	 		  	 By: J.W. Nieuwenhuis
 Title: Jr. Investment
Manager

			
	P.H.C.J. Van Doorne	 		  	B.H.R. Hilterman
			
	 /s/ P.H.C.J Van Doorne
	 		  	 /s/ B.H.R Hilterman

			
	C.M.G. Huijskes	 		  	
			
	 /s/ C.M.G. Huijskes
	 		  	

  
 - 27 - 

					
	On behalf of Debioinnovation SA	  		  	
			
	 /s/ Thierry Mauvernay
	  		  	
	 By: Thierry Mauvernay
 Title: Delegate of the
Board
	  		  	
			
	On behalf of Norgine B.V.	  	                                	  	
			
	 /s/ Peter Stein
	  		  	
	 By: Peter Stein
 Title: Director
	  		  	
			
	On behalf of DHAM N.V.	  		  	
			
	 /s/ Gabriels Sofie
	  		  	
	 By: Gabriels Sofie
 Title: Director
	  		  	
			
	On behalf of Stichting Vogelgezang	  		  	
			
	 /s/ JH Wolkers
	  		  	 /s/ EHM Vehmeijer

	 By: JH Wolkers
 Title: Director
	  		  	 By: EHM Vehmeijer
 Title: Director

			
	On behalf of Hartwig Houdstermaatschappij B.V.	  		  	
			
	 /s/ Rob Defares
	  		  	
	 By: Rob Defares
 Title: Director
	  		  	

  
 - 28 - 

	
	 C. Goddard
  

/s/ C. Goddard
  

	 P. Scalfaro
  

	 /s/ P. Scalfaro

	  
 H. Brulleman

 

	 /s/ H. Brulleman

	  
 K. Schmidt

 

	 /s/ K. Schmidt

  
 - 29 - 

					
	On behalf of Dr. Sixt Holding B.V.	  	                                    	  	Solely for the purpose of Article 1.3, 10 and 12
			
	 /s/ Dr. B.M. Sixt
	  		  	 /s/ Dr. B.M. Sixt

	 By: Dr. B.M. Sixt
 Title: managing
director
	  		  	By: Dr. B.M. Sixt
			
	On behalf of R. Bernards Holding B.V.	  		  	Solely for the purpose of Article 1.3. 10 and 12.
			
	 /s/ Prof. dr. R. Bernards
	  		  	 /s/ Prof. dr. R. Bernards

	By: Prof. dr. R. Bernards	  		  	By: Prof. dr. R. Bernards
	Title: managing director	  		  	
			
	On behalf of L. Van’t Veer Holding B.V.	  		  	Solely for the purpose of Article 1.3. 10 and 12.
			
	 /s/ Dr. L. J. van’t Veer
	  		  	 /s/ Dr. L.J. van’t Veer

	By: Dr. L.J. van’t Veer	  		  	By: Dr. L.J. van’t Veer
	Title: managing director	  		  	
			
	 Solely for the purpose of Article 11.2
  

On behalf of ING Corporate Investments Participaties B.V.

its managing director
 ING Corporate Investments B.V.

its managing director
	  		  	
			
	 /s/ M. Hopman
  
	  		  	
	 By: M. Hopman
 Title: managing director
	  		  	

  
 - 30 - 

 Exhibit 2 - Decision Making 

 

	(A)	 The following matters require the approval of at least 2/3 (two thirds) of the votes cast at a General
Meeting of Shareholders: 

  

	 	(1)	 Any sale or transfer by the Company or any subsidiary of the Company of all or substantially all of its assets
to a third party and any sale or transfer of any material business or material division or of any material rights, assets, clinical programs or intellectual property. 

 

	 	(2)	 Any merger or de-merger of the Company or any subsidiary of the Company
with another entity that is not part of the Company’s group. 

  

	 	(3)	 Any acquisition, divestment or encumbrance by the Company or by any subsidiary of the Company of any asset with
a value in excess of EUR 500,000 in a single transaction or a series of related transactions. 

  

	 	(4)	 Any liquidation or winding up of the Company or any material subsidiary of the Company. 

 

	 	(5)	 Any amendment to the Articles of Association. 

 

	 	(6)	 Any payment of dividends or other distribution on Shares. 

 

	 	(7)	 Any redemption, repurchase or acquisition of any Shares or other equity securities of the Company, other than
repurchases of Shares or other equity securities of the Company pursuant to any existing plans or agreements. 

  

	 	(8)	 Any issuance of Shares, granting options to acquire Shares, any issuance of a new class of shares or any other
securities convertible into Shares or equity securities of the Company and any exclusion of pre-emption rights with respect to Shares and any issue of shares, options, warrants or other equity securities by
any subsidiary of the Company, except to the Company or to a wholly-owned subsidiary of the Company. 

  

	 	(9)	 Any increase or decrease in the number of members of the Supervisory Board. 

 

	 	(10)	 Any unbudgeted incurrence of any borrowing or debt by the Company or any subsidiary of the Company in excess of
EUR 500,000 or providing any guarantee or security rights by the Company or any subsidiary of the Company for any borrowing or debt in excess of EUR 500,000, in each case in a single transaction or a series of related transactions.

  

	 	(11)	 An initial public offering or listing of the Shares or of shares in any subsidiary of the Company and the
appointment of a lead underwriter in connection with such initial public offering or listing. 

  

	(B)	 The following matters require the approval of the Supervisory Board: 

 

	(12)	 Any appointment or dismissal of any member of the Management Board. 

  
 - 31 - 

	 	(13)	 The determination of, and any amendment to. the remuneration of any member of the Management Board.

  

	 	(14)	 Any sale or transfer by the Company or any subsidiary of the Company of all or substantially all of its assets
to a third party and any sale or transfer of any material business or material division or of any material rights, assets, clinical programs or intellectual property. 

 

	 	(15)	 Any merger or de-merger of the Company or any subsidiary of the Company
with another entity that is not part of the Company’s group. 

  

	 	(16)	 Any acquisition, divestment or encumbrance by the Company or by any subsidiary of the Company of any asset with
a value in excess of EUR 500,000 in a single transaction or a series of related transactions. 

  

	 	(17)	 Any liquidation or winding up of the Company or any material subsidiary of the Company. 

 

	 	(18)	 Any redemption, repurchase or acquisition of any Shares or other equity securities of the Company, other than
repurchases of Shares or other equity securities of the Company pursuant to any existing plans or agreements. 

  

	 	(19)	 Any issuance of Shares, granting options to acquire Shares, any issuance of a new class of shares or any other
securities convertible into Shares or equity securities of the Company and any exclusion of pre-emption rights with respect to Shares and any issue of shares, options, warrants or other equity securities by
any subsidiary of the Company, except to the Company or a wholly-owned subsidiary of the Company. 

  

	 	(20)	 Any unbudgeted incurrence of any borrowing or debt by the Company or any subsidiary of the Company in excess of
EUR 500,000 or providing any guarantee or security rights by the Company or any subsidiary of the Company for any borrowing or debt in excess of EUR 500,000, in each case in a single transaction or a series of related transactions.

  

	 	(21)	 Any unbudgeted transaction entered into by the Company or any subsidiary of the Company in excess of EUR
500,000. 

  

	 	(22)	 The adoption of, and any change or amendment to, the Budget. 

 

	 	(23)	 Any instigation or settlement of any litigation or arbitration proceedings by the Company or any subsidiary of
the Company involving an amount exceeding EUR 500,000. 

  

	 	(24)	 An initial public offering or listing of the Shares or of shares in any subsidiary of the Company and the
appointment of a lead underwriter in connection with such initial public offering or listing. 

  
 32 

 Exhibit 3; Letter SFN 

dated 12 Angust 2003, as amended on any subsequent date 

  
 33 

 Exhibit 4. Capitalisation Table 

  
 - 34 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]